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ABSTRACT  
   
Mexican Americans have an increased risk for type 2 diabetes and 
premature cardiovascular disease (CVD). The association of hyperglycemia with 
traditional CVD risk factors in this population has been established, but there is 
limited data regarding other non-traditional CVD risk factors. Thus, this cross-
sectional study was conducted to evaluate CVD risk among Mexican Americans 
by measuring concentrations of lipids, high-sensitivity C-reactive protein 
(hsCRP), and cholesterol in low-density-lipoprotein (LDL) and high-density-
lipoprotein (HDL) subfractions. Eighty overweight/obese Mexican-American 
adults participating in the Maricopa Insulin Resistance Initiative were randomly 
selected from each of the following four groups (n = 20 per group): 
nomolipidemic/normoglycemic controls (NC), dyslipidemic/normoglycemic 
(DN), dyslipidemic/prediabetic (DPD) and dyslipidemic/diabetic (DD). Total 
cholesterol (TC) was 30% higher among DD than in NC participants (p<0.0001). 
The DPD group had 27% and 12% higher LDL-C concentrations than the NC and 
DN groups, respectively. Similarly, LDL-C was 29% and 13% higher in DD than 
in NC and DN participants (p=0.013). An increasing trend was observed in %10-
year CVD risk with increasing degree of hyperglycemia (p<0.0001). The NC 
group had less cholesterol in sdLDL particles than dyslipidemic groups, 
regardless of glycemic status (p<0.0001). When hyperglycemia was part of the 
phenotype (DPD and DD), there was a greater proportion of total and HDL-C in 
sHDL particles in dyslipidemic individuals than in NC (p=0.023; p<0.0001; 
respectively). Percent 10-year CVD risk was positively correlated with 
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triglyceride (TG) (r=0.384, p<0.0001), TC (r=0.340, p<0.05), cholesterol in 
sdLDL(r=0.247; p<0.05), and TC to HDL-C ratio (r=0.404, p<0.0001), and 
negatively correlated with HDL-C in intermediate and large HDL(r=-0.38, 
p=0.001; r=0.34, p=0.002, respectively). The TC/HDL-C was positively 
correlated with cholesterol in sdLDL particles (r=0.698, p<0.0001) and HDL-C in 
sHDL particles (r=0.602, p<0.0001), and negatively correlated with cholesterol in 
small (r=-0.35, p=0.002), intermediate (r=-0.91, p<0.0001) and large (r=-0.84, 
p<0.0001) HDL particles, and HDL-C in the large HDL particles (r=-0.562, 
p<0.0001). No significant association was found between %10-year CVD risk and 
hsCRP. Collectively, these results corroborate that dyslipidemic Mexican-
American adults have higher CVD risk than normolipidemic individuals. 
Hyperglycemia may further affect CVD risk by modulating cholesterol in LDL 
and HDL subfractions. 
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CHAPTER 1 
INTRODUCTION 
Despite a 29.2% decrease in the death rate due to cardiovascular disease 
(CVD) from 1996 to 2006, it remains the leading cause of death among adults in 
the United States (1, 2). In 2006, CVD accounted for 34.2% of total deaths, and 1 
of every 2.9 deaths was related to CVD (1). Recent data showed the prevalence is 
30.7% and 30.9% in Mexican-American men and women, respectively (3). 
Despite a higher prevalence of CVD relative to White Americans, Mexican 
Americans have a lower mortality rate from CVD; however, it remains major 
cause of mortality in this group (4, 5). Therefore, efforts to reduce the progression 
and mortality from CVD in this population are needed.    
Risk factors for CVD include old age, male, diabetes, hypertension, 
smoking, dyslipidemia, and high levels of inflammatory markers (6, 7). The 
prevalence of heart disease is higher in younger men than in women with similar 
risk factors, but after menopause the prevalence increases in women compared to 
men (8). As defined by the National Cholesterol Education Program (NCEP) 
Adult Treatment Panel (ATP) III, the triad of elevated TG, low high-density-
lipoprotein cholesterol (HDL-C) and small-dense LDL (sdLDL) particles are 
independent risk factors for CVD (9). Regarding LDL (low-density lipoprotein), 
having sdLDL particles (pattern B phenotype) poses a higher risk than having the 
more buoyant larger particles (9, 10). Moreover, having a pattern B LDL 
phenotype has been reported to coexist with other features such as dyslipidemia, 
insulin resistance/hyperglycemia, hypertension and hypercoagulability (10). There 
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is scant information regarding the role of HDL particle size on CVD risk. It has 
been suggested that small and large particles may have different capability to 
protect against CVD risk (11). Large HDL particle size is inversely associated 
with CVD, whereas, no such association has been seen with small HDL (sHDL) 
particles (12). Inflammatory factors such as high-sensitivity C-reactive protein 
(hsCRP), and cytokinines are additional risk factors for CVD (6, 7). Various 
research suggest that Mexican Americans tend to have one or many of these blood 
parameters in elevated concentrations, which indicates they are at increased risk 
for CVD (1, 2, 10). Homocysteine is another independent risk factor for CVD 
(13),(14). However, less is known about the relationship between homocysteine 
concentrations and CVD risk. 
The metabolic syndrome (MetS) is a constellation of various risk factors 
of metabolic origin that contribute to the development of atherosclerotic CVD 
(15). Several organizations have their own definition for MetS, depending on the 
criteria used to identify each component (16). As defined by NCEP ATP III (9), 
MetS occurs when there is the presence of three or more of the following risk 
factors: (a) abdominal obesity defined as waist circumference >102 cm in men 
and >88 cm in women, (b) hypertriglyceridemia: >150 mg/dl, (c) low HDL-C: 
<40 mg/dl in men and <50 mg/dl in women, (d) hypertension: > 130 mm Hg 
systolic and > 85 mm Hg diastolic, and (e) fasting hyperglycemia: >100mg/dl. 
Insulin resistance and obesity are considered as the underlying risk factors 
for the MetS and their effect on both CVD and diabetes has been suggested to be 
interrelated (16-18). Whereas insulin resistance is associated with being 
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overweight or obese, not all overweight or obese individuals are insulin resistant 
(18). Nevertheless, insulin resistant individuals commonly have an abnormal fat 
deposition in the abdominal area, either as visceral or subcutaneous fat (15). 
Increased abdominal fat deposition has been associated with insulin resistance 
(15-17). Furthermore, the cluster of abnormalities associated with obesity and 
insulin resistance are dyslipidemia, glucose intolerance, hyperinsulinemia, and 
elevated circulating hsCRP and inflammatory cytokinines (5, 9, 19). It has been 
suggested that Mexican-American men have the highest age adjusted prevalence 
of abdominal obesity, hypertriglyceridemia and high fasting glucose or 
medication use compared to White and African-American men (20). Similarly, 
Mexican-American women also have the highest age adjusted prevalence of 
abdominal obesity, hypertriglyceridemia, low HDL-C and high fasting glucose 
compared to White and African-American women (20). This indicates that 
obesity, insulin resistance and dyslipidemia are becoming more prevalent in this 
group. 
There is limited information about the LDL phenotype, hsCRP, 
homocysteine and their association with CVD risk in Mexican-American adults. 
Therefore, the main objective of this study was to evaluate CVD risk among 
Mexican Americans by measuring concentrations of total cholesterol (TC), LDL-
cholesterol (LDL-C), HDL-C, triglyceride (TG) and hsCRP, as well as cholesterol 
in LDL and HDL particles of different sizes. We further evaluated the association 
between hyperglycemia with a pattern B LDL phenotype, characterized by having 
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a greater proportion of LDL-C in sdLDL particles, or with having greater 
proportion of HDL-C in sHDL particles in Mexican Americans. 
Hypotheses and Aims 
Hypothesis 1: Increased CVD risk in Mexican Americans living in 
Phoenix metropolitan area will be associated with high hsCRP concentrations and 
the presence of a pattern B low-density lipoprotein (LDL) phenotype.  
Specific Aim #1: To estimate CVD risk in Mexican-American adults living 
in the Phoenix metropolitan area by calculating the CVD Framingham risk scores. 
Specific Aim #2: To evaluate the association between independent CVD 
risk factors, including TC, TG, hsCRP, cholesterol in sdLDL and sHDL and CVD 
Framingham risk score in Mexican-American adults living in the Phoenix 
metropolitan area. 
Hypothesis 2: In Mexican Americans, hyperglycemia will be associated 
with having a pattern B LDL phenotype, characterized by having a greater 
proportion of cholesterol in sdLDL particles, and with having a greater proportion 
of HDL-C in sHDL particles. 
Specific Aim #3: To measure the association of hyperglycemia with having 
a pattern B LDL and HDL phenotype, measured by the amount of cholesterol in 
sdLDL particles, and cholesterol and HDL-C in sHDL particles in Mexican 
Americans. 
Research Application 
This pilot research is the initial study designed to estimate prevalence of 
CVD risk among Mexican-American adults living in Phoenix metropolitan area, 
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on the basis of which extensive evidence-based culturally sensitive 
interdisciplinary interventions could be designed and implemented to limit CVD 
risk in this population. 
Delimitations and Limitations 
The study population is limited to Mexican Americans residing in the 
Phoenix metropolitan area; therefore, this study is not generalizable to the other 
Mexican-American or Hispanic groups or to other ethnic groups. Moreover, the 
study is limited to adult participants; the findings of this study will not be 
applicable to other age groups such children, adolescents and elderly. 
This study has a cross-sectional design, with which no causal relationships 
can be established.  In addition, the sample size is relatively small, which may 
limit the statistical power to detect significant associations. All the individuals 
recruited in the study are  30 years and who identify themselves as Mexican-
American; the study does not control for country of birth, acculturation or other 
non-biological factors that may affect CVD risk. Individuals who were previously 
diagnosed with diabetes and/or are currently taking diabetic medication are 
excluded from the study; the presence of other chronic diseases (known or 
unknown) and medication usage may influence the individual results. The study 
did not control for smoking, stress level and other acute illness, which may 
influence hsCRP concentrations. To further evaluate CVD risk among Mexican 
Americans, a longitudinal study that looks upon place of origin, age, gender and 
other genetic as well as behavioral influences is needed. 
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Definition of Terms 
1. Cardiovascular disease (CVD): Term used to group illnesses and events 
that impact the heart and circulating system, including hypertension and 
coronary heart disease. 
2. Cytokinines: Proteins released by cells that have a specific effect on the 
interactions between cells. Various types of cytokines are interlukins, 
lymphokines and tumor necrosis factor that trigger inflammation and 
respond to infections. 
3. Dyslipidemia: Multiple lipoprotein abnormalities occurring 
simultaneously in the same person. These could include elevated TC, 
LDL-C and TG, and reduced HDL-C. 
4. High-density-lipoprotein (HDL): Lipoprotein secreted from the liver and 
small intestine which participates in the reverse cholesterol transport 
process by removing cholesterol from extra-hepatic tissues and returning it 
to the liver.  The concentration of cholesterol circulating in HDL is 
associated with reduced risk of CVD. 
5. Low-density-lipoprotein (LDL): Lipoprotein formed in the circulation 
from very-low-density-lipoprotein (VLDL) through the lipoprotein-lipase-
mediated delipidation cascade carries most of cholesterol in the blood. The 
concentration of cholesterol in LDL is associated with increased risk of 
CVD. 
6. Homocysteine: An amino acid identified as a risk factor for CVD 
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7. High sensitivity C-reactive protein (hsCRP): Acute phase protein 
synthesized by liver due to stress, trauma, illness, inflammation and 
chronic disease condition. Its level is normally low in the blood of healthy 
individual, but rises with an injury, infection, or inflammation and 
disappears when the injury heals or the infection or inflammation goes 
away. It has been suggested that prolonged elevated concentrations of C-
reactive protein increase the risk for CVD, hypertension, diabetes, and 
MetS. 
8. Insulin resistance: It is the diminished ability of cells to respond to the 
action of insulin. Insulin stimulates entrance (absorption) of glucose from 
bloodstream to various body cells (tissue) and also contributes in 
utilization of the absorbed glucose in the body tissues. Therefore, when 
insulin resistance occurs the pancreas secretes excess insulin, 
hyperinsulinemia, in an attempt to regulate blood glucose. 
9. Metabolic syndrome (MetS): The MetS is a constellation of various risk 
factors of metabolic origin that contribute to the development of 
atherosclerotic CVD. As defined by NECP ATP III, it occurs when there 
is the presence of three or more of the following risk factors: (1) 
abdominal obesity defined as waist circumference >102 cm in men and 
>88 cm in women, (2) hypertriglyceridemia: >150 mg/dl, (3) low HDL-C: 
<40 mg/dl in men and <50 mg/dl in women, (4) hypertension: > 130 mm 
Hg systolic and > 85 mm Hg diastolic, and (5) fasting hyperglycemia: 
>110mg/dl.  
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10. Small, dense LDL (sdLDL): The sub-fraction of LDL particles that differ 
significantly in size, density, composition and other physiochemical 
properties, and are characterized by sdLDL phenotypic (determined by 
both genetic make-up and environmental influences) particle size that has 
greater atherogenic potential compared to buoyant large LDL particles. 
The increased atherogenicity is due to its increased permeability to the 
sub-endothelial space and lower resistance to oxidative stress. 
11. Pattern B LDL phenotype:  Presence of greater proportion of LDL-C in 
the sdLDL particles. 
12. Subcutaneous fat: Fat that is accumulated beneath the epidermis 
(outermost layer of the skin) and is a protective wrap over the body’s 
surface. 
13. Visceral fat: Fat that is accumulated predominantly in the intra-abdominal 
(peritoneal) cavity, and is also known as organ fat. 
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CHAPTER 2 
REVIEW OF LITERATURE 
Cardiovascular Disease: Prevalence and Mortality 
Cardiovascular disease (CVD) refers to the diseases that affect
 
the heart 
and blood-vessels (21).  This includes coronary heart disease
 
(CHD) or coronary 
artery disease (CAD) characterized by impaired blood flow in the coronary 
arteries that can result in angina, myocardial infarction, and sudden death (21). 
Other forms of CVD that can also result in death are stroke, peripheral vascular 
disease, and congestive heart failure (22). CVD is the leading cause of death 
around the world in both developed and developing countries (1). In 2006, 41.3 
million women (34.9%) and 38.7 million men (37.6%) were living with CVD 
around the world, and the worldwide death rate due to CVD was 262.5 per 
100,000 (2). In the same year in the United States (US) 25.8% of deaths were due 
to CVD in women (1). Similarly, 26% of deaths among men were related to CVD 
(2).  Although in the US CVD death rates declined by 27.8% from 1997 to 2007, 
CVD still accounted for 33.6% (813,804) of all 2,426,264 deaths in 2007 (1).  
Looking at health disparities in the US, premature mortality
 
due to a major 
cardiovascular event has been often related to racial/ethnic differences (23). In 
2003, the highest percentage of premature mortality from CHD was observed in 
American Indians (34%), followed by Blacks (28%), Asians or Pacific Islanders 
(21%) and Whites (16%); however, some of these differences
 
could be due to the 
age distributions of these groups (23). 
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There are several risk factors identified for CVD. Most of these risk 
factors are modifiable by making certain lifestyle-related/behavioral changes such 
as eating a regular healthful diet and performing regular physical activity. These 
alterations in lifestyle could further change the severity of the modifiable risk 
factors and lower the prevalence of cardiovascular events. The major modifiable 
risk factors for CVD are smoking, physical inactivity, hypertension, dyslipidemia, 
insulin resistance, diabetes, excess body weight (especially around the abdominal 
area), physical inactivity, proatherogenic diet (diet that are high in saturated and 
trans-fatty acids), and proinflammatory states (such as high concentrations of 
hsCRP, homocystein, fibrinogen) (8).  These will be discussed in detail in the 
CVD risk factors section. 
Some of the risk factors that are not modifiable are age, gender and 
genetic predisposition. At a younger age, men have a greater risk for CVD than 
women; however after menopause the risk among women increases and surpasses 
that of men of the same age (8). Genetic predisposition, in other words, having a 
family history of any kind of CVD, also increases CVD risk (8).  
CVD Risk in Mexican Americans 
Hispanics are the fastest growing minority group in the US and constitute 
16.3% of the total US population (24). Mexican Americans constitute 63% of the 
Hispanic population (24). As it is for other ethnic groups residing in the US, CVD 
is the leading cause of mortality and disability among Mexican-American adults 
(25).  Based on age adjusted estimates from the 2009 National Health Interview 
Survey (NHIS), the prevalence of CVD is 30.7% and 30.9% in Mexican-
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American men and women, respectively. Data from a 7- to 8-year follow-up in 
the San-Antonio Heart Study indicated 30% more age-and-sex-adjusted CVD-
related deaths among Mexican Americans than among non-Hispanic Whites (24). 
In this study risk factors such as current smoking, diabetes, high cholesterol, and 
hypertension were positively associated with CVD mortality in Mexican 
Americans, and all of these risk factors together contributed to 55% of overall 
CVD related deaths in Mexican Americans (24). In addition, community based 
surveillance validated that the mortality rate among Mexican-American men and 
women was 12% and 36% greater, respectively, than among their White 
counterparts (26). 
Many comparative studies have found that Mexican Americans, in 
comparison with non-Hispanic Whites, have higher prevalence of CVD risk due 
to the greater presence of CVD related risk factors such as physical inactivity, 
abnormal fat deposition and obesity, and diabetes mellitus, despite having lower 
prevalence of hypertension (27-36). According to NHIS 2009, Hispanics are more 
likely to report physical inactivity (44%) than White Americans (28.4%) (34). 
Furthermore, according to NHANES 2007-2008 data, 80% of Mexican-American 
men and 77% of Mexican-American women were either overweight or obese 
(33). Moreover, NHANES data set from 2004-2006 indicated that 10.4% of 
Hispanic including Mexican-American adults had diagnosed diabetes compared to 
6.6% of their White counterparts (32). Although hypertension is less common 
among Mexican Americans than in White Americans, the awareness and 
treatment of the disease are lower (35.2%) compared to White Americans (46.1%) 
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(35). However, according to NHIS 2006-2008 data, Hispanic adults were less 
likely to be current cigarette smokers (men 18.4% and women 9.4%) than White 
adults (men 24% and 21%) (36). 
Metabolic Syndrome 
The metabolic syndrome is a cluster of risk factors for CVD and diabetes 
(type 2) that co-occur in the same individual (37). Although several definitions of 
the metabolic syndrome have been proposed, according to the National 
Cholesterol Education Program’s Adult Treatment Panel III, the presence of 
metabolic syndrome is diagnosed when at least 3 of the following 5 risk factors 
are present: (a) fasting plasma glucose >100 mg/dL or undergoing drug treatment 
for elevated glucose; (b) HDL-C <40 mg/dL in men or <50 mg/dL in women or 
undergoing drug treatment for reduced HDL-C; (c) TG >150 mg/dL or 
undergoing drug treatment or elevated TG; (d) waist circumference >102 cm in 
men or >88 cm in women; and (e) blood pressure >130 mm Hg systolic or >85 
mm Hg diastolic or undergoing drug treatment for hypertension (37).  
Using data from the Framingham Offspring Study from 1987-2007, 
Franco et al. (38) examined the probability of having metabolic syndrome, and 
probability of having CVD morbidity and mortality in the presence of specific 
combinations
 
of any 3 components of the metabolic syndrome. In this cohort, 
hypertension was the most
 
frequent component that was present at the diagnosis 
of metabolic syndrome (77.3%). The presence of central obesity increased the risk 
of developing metabolic syndrome by 4.75-fold. Moreover among participants 
who were diagnosed with metabolic syndrome, the joint presence of central 
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adiposity, hypertension, and hyperglycemia increased the likelihood of having a 
cardiovascular event by 2.36-fold and the risk of mortality from CVD by 3-fold 
(38). 
According to data from NHANES, in 2003 to 2006 about 34% of adults 
met the criteria for metabolic syndrome; the age-adjusted prevalence was 35.1% 
for men and 32.6% for women (39). Among different race/ethnic groups, the age-
adjusted prevalence of metabolic syndrome among men was 37.2%, 25.3%, and 
33.2% for Whites, Blacks, and Mexican Americans, respectively. Among women, 
the prevalence was 31.5%, 38.8%, and 40.6%, respectively (39). These data 
indicate that the prevalence of metabolic syndrome is in part dependent on sex 
and race/ethnicity. 
 In the Atherosclerosis Risk in Communities (ARIC) Study, among the 
components of the metabolic syndrome, elevated blood pressure and low levels of 
HDL-C exhibited the strongest associations with CHD. In this study, men and 
women with the metabolic syndrome were 1.5 and 2 times more at risk for 
developing CHD than participants who had parameters within normal ranges, 
after adjustment for age, smoking, LDL-C, and race/ethnicity (40).  
In summary, elevated blood pressure, overweight/obesity, 
diabetes/glucose intolerance/insulin resistance and dyslipidemia are all major 
modifiable CVD risk factors that contribute towards the development of the 
metabolic syndrome (38-40). Thus, by having a cluster of risk factors, individuals 
with metabolic syndrome are at greater risk of developing CVD. Therefore, 
identification of individuals with the metabolic syndrome may provide 
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opportunities to intervene earlier in the development of shared disease pathways 
that predispose individuals to both CVD and/or diabetes. 
CVD Risk Factors 
Given the increasing burden of heart disease in modern society, there is a 
growing emphasis on detecting CVD risk factors in individuals who could benefit 
from targeted preventive efforts.  This section will focus on describing the main 
modifiable CVD risk factors. 
Smoking  
Smoking is the major modifiable risk factor for the development and 
progression of CVD including CHD, stroke, peripheral vascular disease, and 
congestive heart failure (22). From 1998 to 2009, the percentage of US adults 
who were current cigarette smokers declined from 24.1% to 20.6% (36). In 2009, 
among American adults, 23.1% of men and 18.1% of women were current 
cigarette smokers (41). Between 2000 and 2004, the direct medical costs ($96 
billion) and lost productivity costs ($97 billion) associated with smoking summed 
up to an estimate of $193 billion per year (42). 
According to a study conducted in Hispanic men (20-74 years old), age-
adjusted cigarette smoking rates were the lowest among Mexican-American men 
(33.8%) compared to Puerto Rican (52.3%) and Cuban-American men (64.1%) 
(43). Other research studies have also shown that Mexican-American adults have 
lower smoking rates than other ethnic groups (44, 45).  
Cigarette smoking has been associated with established, traditional, CVD 
risk factors such as higher serum cholesterol concentrations, coronary vasomotor 
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reactivity, platelet aggregation, and prothombotic states (43). Cigarette smoking 
has also been associated with novel risk factors for CVD such as increased levels 
of oxidative stress, production of oxidants and higher levels of inflammatory 
markers like serum C-reactive protein (CRP) (44, 45). 
The presence of oxidants and inflammation are important mechanisms by 
which smoking promotes atherosclerotic plaque formation. Smoking promotes 
oxidative stress, in other words- oxidation of lipids, proteins, and DNA leading to 
cellular damage, which further leads to atherosclerosis (46, 47). Oxidative stress 
occurs when there is an imbalance between the production of oxidants and 
endogenous protective antioxidants. Smoking stimulates the generation of 
reactive oxygen species (ROS) such as oxidized LDL, which is taken up by 
macrophages, an important step in the development of foam cells that are found 
atherosclerotic lesions (46). Furthermore, the ROS formed during smoking 
decrease nitric oxide (NO) release and bioavailability (46). NO plays a vital role 
in regulating endothelial function and platelet activation and aggregation, and at 
normal levels it inhibits smooth cell proliferation and adhesion of monocytes to 
the endothelium (46, 47). Therefore, the impairment of endogenous NO release 
contributes to acute cardiovascular events as well as accelerated atherosclerosis 
(47). Moreover, smoking promotes a chronic inflammatory state that leads to 
increased white blood cells (neutrophils) count. The neutrophils are associated 
with a greater long-term cardiovascular reactivity by releasing ROS proteases and 
leukotrienes (38) that, in turn, cause endothelial cell injury and the aggregation 
and activation of platelets. Thus, smoking not only stimulates generation of ROS, 
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but also inhibits NO release and bioavailability, promotes inflammation, causes 
endothelial cell injury that together put individuals at increased risk of developing 
CVD. 
Physical Inactivity 
Physical inactivity refers to not getting the recommended level of regular 
physical activity. According to the US department of health and human services, 
the physical activity guidelines for Americans published in 2008 recommend that 
for health benefits, adults (18-64 years old) should do at least 150 minutes (two 
hours and thirty minutes) per week of moderate-intensity, or 75 minutes (one hour 
and fifteen minutes) per week of vigorous-intensity aerobic physical activity, or 
an equivalent combination of moderate- and vigorous-intensity aerobic activity 
(48). Aerobic activity should be performed in episodes of at least 10 minutes, and 
it should be spread throughout the week (48). For additional and more extensive 
health benefits, adults should increase their aerobic physical activity to 300 
minutes (five hours) a week of moderate-intensity, or 150 minutes a week of 
vigorous-intensity aerobic physical activity, or an equivalent combination of 
moderate- and vigorous-intensity activity (48). Adults should also engage in 
muscle-strengthening activities that are moderate or high intensity and involve all 
major muscle groups on two or more days a week to reduce the risk for chronic 
diseases and disabilities (48, 49). 
Activities such as running, swimming, heavy gardening in the leisure time 
are known as leisure-time physical activities, and activities such as heavy 
household chores and strenuous job activities are known as job-related physical 
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activity (50). Various prospective epidemiological studies
 
concentrating on 
leisure-time physical activity have consistently
 
documented a reduced incidence 
of cardiovascular events in the more physically
 
active participants (27, 51, 52).  
Data from the NHIS survey 2009 demonstrated that 30% of US adults do not 
engage in leisure time physical activity, defined as “no moderate-intensity 
physical activity for 30 minutes 5 days a week or vigorous-intensity physical 
activity for 20 minutes 3 days a week” (41). In addition, according to this data, the 
proportion of adults reporting regular leisure-time activity was positively 
associated with education level: 46.0% of people with a college degree or higher 
were regularly active compared with 21.4% of adults with less than a high school 
diploma (41). Furthermore, the age-adjusted prevalence of physical inactivity was 
higher among women than in men (34.5% vs. 30.3%) (41).  
Race/ethnic disparities in physical activity exist among the adult 
population residing in the US. According to NHIS 2009 data, the age-adjusted 
prevalence of physical inactivity was higher among Blacks and Hispanics than in 
Whites (87% and 44% vs. 28.4%) (41). Although Hispanics engage considerably 
more in occupational physical activity than White Americans, leisure time 
inactivity is 2.5 times higher in Mexican Americans compared to their White 
counterparts (53). Moreover, leisure-time physical inactivity is greater among 
Spanish-speaking Mexican-American adults relative to their English-speaking 
counterparts, independent of place of birth (53). Among Mexican Americans, the 
level of leisure time physical activity has been reported to be affected by several 
factors, such as environmental barriers, economic barriers, and limited access to 
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health education and culturally appropriate health-related materials (5, 53, 54).   
Economic barriers such as lower level of education, higher levels of physical 
activity at work, as well as time spent generating income may compete with the 
time available for leisure time physical activity among Mexican Americans (53). 
Education influences health through lifestyle behaviors such as exercise and diet, 
problem-solving capacity and values; therefore, if culturally appropriate health 
related materials and education are not available to minority populations such as 
Mexican Americans, it will be difficult to reach out for health and lifestyle related 
information (5, 53). Along with the economic deprivation, environmental barriers 
such as family responsibilities, social norms, lack of social support and social 
isolation leads to lower readiness, willingness, and ability to participate in regular 
leisure time physical activity in this minority group (54). However, information 
on how these factors specifically affect physical activity among Mexican 
Americans is limited. 
The precise mechanisms through which physical activity lowers CVD risk 
are not completely understood. Prior studies have demonstrated favorable effects 
of physical activity on traditional CVD risk factors. In a study design of a total of 
111 sedentary, overweight men and women with mild-to-moderate dyslipidemia 
were randomly assigned to participate for six months in a control group or for 
eight months in one of three exercise groups: high-amount–high-intensity 
exercise, the caloric equivalent of jogging 20 miles per week at 65-80 % of peak 
oxygen consumption; low-amount–high-intensity exercise, the equivalent of 
jogging 12 miles per week at 65-80 % of peak oxygen consumption; or low-
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amount–moderate-intensity exercise, the equivalent of walking 12 miles per week 
at 40-55 % of peak oxygen consumption. This study found a high-amount-high-
intensity of regular exercise, even in the absence of clinically significant weight 
loss, can significantly improve the overall lipoprotein profiles, i.e. concentrations 
of lipids and increase in the concentrations of larger LDL and HDL subfractions 
(55). Moreover, the data revealed that exercise of low-amount-moderate-intensity 
significantly decreased the concentrations of cholesterol in sdLDL and 
concentration of sdLDL particles, and increased the average size of LDL 
particles, even when plasma LDL-C concentration was not changed (55). The 
same low-amount-moderate-intensity of exercise also increased the total HDL-C 
concentration, the concentration of large HDL particles, and the average size of 
HDL particles and decreased the concentrations of TG and total VLDL- TG at the 
margin of statistical significance (55). Similarly, data from another study 
conducted with overweight sedentary females revealed that after 12-months of 
treatment with exercise (either vigorous intensity/high duration; moderate 
intensity/high duration; moderate intensity/moderate duration; or vigorous 
intensity/moderate duration) and diet (energy intake between 1200 and 1500 
kcal/d and dietary fat intake between 20% and 30% of total energy intake), the 
participants in all groups achieved significant weight loss (p<0.01) and increase in 
cardiorespiratory fitness level (p=0.04); regardless of different exercise durations 
and intensities (56). In addition, several research studies have shown that the 
regular physical activity may work through additional biological mechanisms to 
reduce coronary risk by reducing inflammatory and hemostatic markers as well as 
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traditional CVD risk factors. The inverse association between physical activity 
and CVD continues even after adjustments for traditional CVD risk factors, such 
as blood pressure, lipids, and adiposity (27). The protective effect has been in part 
attributed to reduced inflammation.  A study that had a six-week aerobic physical 
training session improved the inflammatory markers in adults with existing stable 
CVD; CRP concentrations decreased by 23.7% and plasma vascular cell adhesion 
molecule-1 (VCAM-1) concentrations declined by 10.23% (29). Similarly data 
from a study with 27,055 healthy women confirmed the inverse relation between 
physical activity and CVD risk (28). In this study inflammatory/hemostatic 
biomarkers and blood pressure were the largest contributors for CVD (32.6% and 
27.1%, respectively) that were favorably modified with physical activity.  
Dyslipidemia 
Dyslipidemia, a major modifiable risk factor for CVD, is defined as either 
one or a combination of elevated fasting concentrations of LDL- C and TG, and 
low levels of HDL-C that contributes to atherosclerosis (1). Dyslipidemia can 
occur due to both modifiable and non-modifiable factors. The most important 
secondary cause of dyslipidemia in developed countries is a sedentary lifestyle 
with excessive dietary intake of saturated fat, cholesterol, and trans-fats. Other 
common modifiable cause of dyslipidemias are: diabetes, alcohol overuse, 
chronic kidney disease, hypothyroidism, primary biliary cirrhosis and other liver 
diseases, and usage of drugs, such as thiazides, β-blockers, retinoic acid, highly 
active antiretroviral agents, estrogen and progestin, and glucocorticoids (57). 
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There are also non-modifiable risk factors for dyslipidemia due to genetic 
predisposition related to the presence of single/multiple gene mutations that result 
in either overproduction or defective clearance of TG and LDL-C, or in 
underproduction or excessive clearance of HDL-C (57). Some of the examples 
are: familial hypercholesterolemia, familial defective apoprotein B100 (apo B100), 
LPL deficiency, apoprotein C2 (apo C2) deficiency, familial hypertriglyceridemia, 
familial combined hyperlipidemia, familial dysbetalipoproteinemia and familial 
LCAT deficiency, familial HDL deficiency, hepatic lipase deficiency and 
sitosterolemia (57). The dyslipidemia caused by genetic defects are less common 
compared to the dyslipidemia attributed by other modifiable factors (58, 59).  
In the United States, dyslipidemia especially elevated TC and LDL-C are 
important risk factors for CVD (59). In addition, diabetic dyslipidemia, 
characterized by having elevated TG and low HDL-C further exacerbates the 
CVD risk among individuals with diabetes (57). Data from NHANES 2005-2008 
reported that 16.2% of the US population had hypercholesterolemia, but the age-
adjusted prevalence of high LDL-C in the US adults decreased from 1988-1994 
(26.6%) to 1999-2004 (25.3%). This reduction in prevalence could be due to 
increased awareness (24%), use of pharmacological lipid-lowering treatment 
(29%), and LDL-C control (21%) (60, 61).  
Although all of the components of dyslipidemia individually increase 
CVD risk, research supporting causality is strongest for elevated TC and LDL-C 
concentrations (59). A large longitudinal study recruiting participants for the 
Multiple Risk Factor Intervention Trial has demonstrated a continuous positive 
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relationship of TC with risk of CVD; there was a low incidence of CVD among 
individuals with a low TC concentration, even in the presence of other risk factors 
such as smoking and hypertension (62). Recently, longitudinal studies have 
reported that the concentration of apo B100, the major apoprotein carried by LDL, 
is a stronger predictor of CVD than LDL-C (63, 64). 
Although LDL-C and TC are considered key components in the 
atherosclerosis that leads to CVD, prospective studies have suggested HDL-C and 
TG also have an effect on CVD risk; therefore they are the secondary lipid targets 
for therapeutic interventions (65). Prospective studies have demonstrated a strong 
inverse association between HDL-C and CVD; it has been estimated that with 
each 1 mg/dL decrease of HDL-C the risk for CVD events increases by 2%, 
whereas the risk for CVD events is reduced by 6% with each 1 mg/dL increase of 
HDL-C (65). Data from a longitudinal study that followed men and women from 
1972 to 1976 reported an inverse correlation between HDL-C and CVD mortality, 
particularly for women, after controlling for age, LDL-C, TG, BMI, systolic blood 
pressure and smoking (24). There is also evidence of a strong inverse association 
between the concentration of apoprotein A1 (apo A1), the major apoprotein in 
HDL, and CVD risk due to its antiatherosclerotic properties. (66, 67). Regarding 
TG, the studies supporting hypertriglyceridemia as an independent risk factor for 
CVD are not as strong as other lipid components because the TG concentration is 
influenced by biological factors such as physical inactivity, obesity, excess 
alcohol consumption (68). However, hypertriglyceridemia further increases the 
risk of CVD by increasing sdLDL particles, mainly due to greater synthesis of 
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VLDL, and it is an independent risk factor for metabolic syndrome (63, 68). 
Several cohort studies together provided an evidence of greater direct independent 
association between TG and CVD risk in women than in men; however, this 
relation was lost when controlled for HDL-C (69, 70). 
There are several reports documenting differences in lipid profiles among 
people from various ethnic/racial backgrounds. An earlier NHANES report (data 
from 1999-2002) including 2,256 Mexican-American and 4,624 non-Hispanic-
White adults (>20 years) indicated that Mexican Americans had lower prevalence 
of dyslipidemia than non-Hispanic Whites (31% vs. 35%) (71). Mexican 
Americans also had lower awareness (33% vs. 56%) and lower pharmacotherapy 
treatment rates for dyslipidemia (14% vs. 30%) than Whites (71).  In contrast, 
more recent NHANES data (2005-2008) shows that the lipoprotein profile of 
Mexican Americans is in fact more atherogenic than that of Whites (1). Mexican-
American men have about 6% more LDL-C, 3% less HDL-C and 13% more TG 
than White men. Among women, Mexican-Americans had almost similar LDL-C, 
8% less HDL-C and 8% more TG than White women (1). Similarly, a study in 
hypertensive adults including 1,286 non-Hispanic Black and 1,070 non-Hispanic 
White participants reported about 1.5 times greater prevalence as well as 2.7 times 
greater treatment and 1.8 times greater control of dyslipidemia among Whites 
than in Blacks (72). Nevertheless, awareness and treatment for dyslipidemia 
continues being inadequate among Hispanics. Among four different ethnic groups 
participating in the MESA 2000-2002 study, Black and Hispanics, were 
approximately15% and 20% less likely to be treated, and both (Blacks and 
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Hispanics) were approximately 30% less likely to be controlled than Whites; 
Chinese Americans, on the other hand, were 20% less likely to have dyslipidemia, 
with no differences in treatment and control rates for dyslipidemia than Whites 
(73).  
Lipoproteins 
There are different types of lipoproteins that vary in function and size 
depending upon the ratio of lipid to protein within the particle, and in having 
different proportions of lipid and different apoproteins (74). Such composition 
differences influence the density of the particle, which further helps to classify the 
various lipoproteins. In order of lowest (the most concentration of lipid) to highest 
density, the lipoprotein fractions are: chylomicrons, very-low-density lipoproteins 
(VLDLs), intermediate-density lipoproteins (IDLs), low-density lipoproteins 
(LDLs), and high-density lipoproteins (HDLs) (74).  
Very-Low-Density-Lipoproteins (VLDL) 
 VLDL is synthesized in the liver. It contains one apo B100 molecule per 
particle, as well as other apoproteins (C and E). The main functions of VLDL are 
to carry TG to extra hepatic tissues and exchange lipids with HDL; when 
cholesteryl esters transferred from HDL to VLDL via cholesterol ester transfer 
protein (CETP), while TG and phospholipids are transferred from VLDL to HDL 
(75). The VLDL is larger in size because of its large TG content and thus can 
carry more molecules of cholesterol ester per particle than LDL (75).  
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Intermediate-Density-Lipoproteins (IDL) 
 IDL is an intermediate between VLDL and LDL and can also be called a 
VLDL remnant. It has a short half-life in the bloodstream and has a little 
physiological importance (74), although the level remains high during 
hypertriglyceridemia. IDL originates in the blood, when TG is removed from 
VLDL, during the delipidation cascade or via CETP activity (76). Therefore, IDL 
has a greater proportion of cholesterol and cholesteryl esters than VLDL. 
Low-Density-Lipoproteins (LDL) 
 LDL is formed in the intravascular compartment from VLDL and IDL. Of 
the total amount of the proteins in LDL, about 98% are apo B100. LDL is the 
major carrier of cholesterol esters in humans (74). The plasma concentration is 
determined by the rate of entry into the plasma and rate of clearance by the liver 
and extra hepatic tissues (74). The main function of LDL is to work as a major 
carrier of cholesterol, by transporting cholesterol from plasma to the peripheral 
tissues or liver for its use in cellular metabolism such as conversion into other 
metabolites, membrane construction and storage (74).  Heterogenity of LDL is 
associated with different degrees of atherosclerotic risk; sdLDL is more 
susceptible to oxidation and therefore more atherosclerotic than large buoyant 
LDL (77). 
High-Density-Lipoproteins (HDL) 
HDL is made in the liver as well as in the intestine (74). It is a smaller and 
denser lipoprotein with higher protein content, but does not have apo B. Its 
primary role is to transport cholesteryl ester back to the liver, but it also plays a 
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role in reverse cholesterol transport, i.e. movement of cholesterol from peripheral 
tissues to the liver, and exchange of TG for cholesteryl ester with TG-rich 
lipoproteins such as VLDL and IDL through the action of CETP (78). The amount 
of HDL-C in the circulation is inversely related to atherosclerosis and coronary 
artery disease risk due to its 4 major protective properties: (1) antioxidant: it 
prevents lipid peroxide formation, removes lipid oxidation products from LDL 
and reduces monocyte-endothelial cell interaction induced by oxidized LDL; (2) 
anti-inflammatory: it reduces endothelial-derived adhesive proteins and hence 
macrophages binding and transmigration; (3) it improves endothelial function 
through restoration of endothelial nitric oxide synthase (eNOS) production, 
enhancement of endothelium-dependent vasodilation, inhibition of endothelin-1 
synthesis, and maintenance of endothelial cell integrity by preventing apoptosis, 
migration and proliferation; and (4) antithrombotic: it increases blood flow 
through nitric oxide and prostacyclin production (75, 79). 
HDL is secreted by the liver as a nascent HDL that contains apo A1. As 
these nascent HDL particles move into the circulation, they pick up free 
cholesterol and phospholipids (79). The apo A1acts as a reservoir for the 
phospholipids, allowing itself to bind to cholesterol released from cells, which is 
subsequently esterified on the surface of the HDL by the activity of the 
lecithin:cholesterol acyl transferase (LCAT) enzyme (79, 80). The hydrophobic 
cholesterol ester then moves to the core of the HDL particle and as the amount of 
cholesterol ester increases, the particle becomes larger and more spherical, 
forming HDL3 particles. The esterified cholesterol in HDL3 is then exchanged for 
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TG in apo B containing particles such as VLDL, IDL and their remnants via 
CETP activity, which generates the larger TG-rich HDL2 particles (80, 81). The 
hepatic lipase (HL) then hydrolyzes the TG of HDL2 thereby generating sHDL 
particles that are taken up by the receptors located at the hepatic cells (80).  
Chylomicrons 
 Chylomicrons are re-formed derivatives from exogenous sources (dietary 
fats) that are primarily synthesized in the intestine (some species formed in liver 
as well) (74). An important role of chylomicrons is to transport exogenous dietary 
lipids to tissues other than the liver such as adipocytes and muscle (74). Because 
TGs are the most abundant lipids found in the diet, chylomicrons also have 
abundance of triglycerides. Apoproteins that are found in chylomicrons are apo A, 
apo B48, apo C and E (acquire from HDL while in circulation). Chylomicrons are 
transported by the blood throughout the tissues, while undergoing intravascular 
hydrolysis at certain tissue sites like muscle and adipose tissue. This hydrolysis 
occurs through the action of the enzyme lipoprotein lipase (LPL). Hydrolysis of 
chylomicrons releases free fatty acids and diacyglycerols that are quickly 
absorbed by the extra-hepatic tissues (74). 
Chylomicron Remnants 
 The chylomicron remnant is a smaller particle that is less rich in TGs, but 
richer in cholesterol and cholesterol esters, which remain after the lipolytic action 
of LPL on chylomicrons. These remnants are removed from the circulation by the 
liver cells endocytosis following interaction of the remnant particles with specific 
receptors apo C or apo E receptors present in the liver cells (82).  
  28 
Lipoprotein Metabolism and Development of Atherosclerosis  
Lipoproteins are a diverse class of carrier particles that contain varying 
amounts of TG, cholesterol, phospholipids and proteins. Their roles are to 
transport lipids in the intravascular circulation. Figure 1 shows the intravascular 
metabolism of lipoproteins. The cholesteryl ester that is formed in the liver is 
incorporated into the nascent TG-rich lipoprotein VLDL. As VLDL travels into 
the circulation, some of the TGs are taken up by extra hepatic tissues via the 
action of the enzyme lipoprotein lipase (LPL), forming IDL, and ultimately LDL. 
Both IDL and LDL can go back to the liver via LDL receptor-mediated uptake. 
Circulating cholesterol can also be transferred back to the liver through the 
“reverse cholesterol transfer process” (79). For this process, HDL removes 
cholesterol from the extra hepatic tissues, and carries it back to the liver; the 
intravascular cholesterol esterification is done by the activity of the enzyme, 
LCAT, which mainly occurs within HDL (79).  
Apoproteins are the protein portion of lipoproteins. They mainly serve as 
structural components of the lipoproteins. Their functions include increasing 
solubility, recognition sites for cell surface receptors, and activators or coenzymes 
for lipoprotein metabolism (74). Each lipoprotein particle has one or more 
apoproteins. According to the structure and function, apoproteins are divided into 
several classes and subclasses, but the function of all is not yet understood. 
Apoprotein-A1 (apo A1) is the major apoprotein in HDL and is a main activator 
for the enzyme, LCAT (74). It also has an anti-inflammatory and antioxidant 
properties. Apoprotein-B100 (apo B100) is synthesized in the liver and is present in 
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VLDL, IDL and LDL. It is also a ligand for the LDL receptors in the liver and 
extrahepatic tissues. Apoprotein-C2 (apo C2) is also synthesized in liver, and is 
transferred into the circulation in HDL. It is picked up by VLDL while circulating 
in lymph and blood, and is also an activator for LPL (78, 79). In contrast, apo C3 
inhibits LPL activity, and could interfere with apo-C2-mediated activation of LPL 
when it is abundant within VLDL particles. Apoprotein-E (apo E) is also an 
important factor of the fate of VLDL-TG, since it displaces apo-C2, thus 
interfering with LPL activation (74). In addition, it is a ligand for chylomicron 
remnant receptor as well as LDL receptor in the liver (74). 
 Atherosclerosis is a form of chronic inflammation resulting from 
interaction between modified lipoproteins, monocytes-derived macrophages, T-
cells and the normal cellular elements of the arterial wall. While LDL plays an 
essential role as a vehicle for the delivery of cholesterol at the peripheral tissue, 
macrophages play a central role in the atherogenic process by modulating the lipid 
metabolism (83). The recruitment of macrophages to lesion-prone sites of large 
arteries is regulated by cell adhesion molecules such as vascular cell adhesion 
molecule-1 (VCAM-1), inter-cellular adhesion molecule-1 (ICAM-1) that are 
expressed on the surface of endothelial cells in response to inflammatory stimuli 
(83). Further, migration of macrophages into the artery wall is likely to be 
stimulated by oxidized LDL, which can directly attract monocytes (83). The 
accumulation of cholesterol-loaded macrophages, or “foam cells”, in the arterial 
wall is the representation of atherosclerotic lesion (83, 84). The transition from 
the relatively simple fatty streak to the more complex lesion is characterized by 
  30 
the immigration of smooth muscle cells from the medial layer of the artery wall 
past the internal elastic lamina and into the intimal, or sub-endothelial, space. 
Intimal smooth muscle cells may proliferate and take up modified lipoproteins, 
contributing to foam cell formation, and synthesize extracellular matrix proteins 
that lead to the development of the fibrous cap (84). This phase of lesion 
development is influenced by interactions between macrophages and T-cells that 
result in a broad range of chronic inflammatory state. Although advanced 
atherosclerotic lesions can lead to ischemic symptoms as a result of progressive 
narrowing of the vessel lumen, acute cardiovascular events that result in 
myocardial infarction and stroke are generally due to the plaque rupture and 
thrombosis (83, 84). Plaque rupture exposes plaque lipids and tissue factor to 
blood components, initiating the coagulation cascade, platelet adherence, and 
thrombosis. 
LDL Subfractions 
 According to ATP III, high-circulating LDL-C concentrations still remain 
the primary cause of CVD (9). Although the association between LDL-C 
concentrations and
 
CVD has been well established, a relatively high proportion of 
individuals
 
with CVD have plasma LDL-C concentrations in the normal range. 
LDL particles are heterogeneous according to their size, density,
 
composition, and 
physicochemical properties (77). LDL can be separated into seven different kinds 
of particles, and based on size of particles and concentration of cholesterol in 
these particles, it is possible to have two main LDL phenotypes: LDL subclass A 
(phenotype A) is characterized by having large and buoyant LDL particles and 
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having greater concentration of cholesterol in larger LDL particles, and LDL 
subclass B (phenotype B) is characterized by having small, dense LDL(sdLDL) 
particles and having greater concentration of cholesterol in sdLDL particles (85). 
It has been reported that the presence of sdLDL particles increases the risk of 
coronary artery disease threefold even at normal cholesterol concentrations (77).  
The association between phenotype B and increased risk for CAD was first 
demonstrated in retrospective studies(86, 87) and was later supported by 
prospective studies (88, 89). The small dense particles are formed by an exchange 
of lipids between LDL and TG-rich lipoproteins such as VLDL and IDL. The 
cholesteryl ester contained in the core of LDL particles is exchanged for TG by 
CETP; HL increases lipolysis of TG-rich LDLs, reducing the core volume of the 
particles (90). The formation of sdLDL particles increases with the presence of 
TG-rich lipoproteins. Thus, there is a positive correlation between TG and 
sdLDL. The sdLDL particles do not present themselves alone but exist together 
with the condition such as dyslipidemia, hypertension, insulin resistance and 
hypercoagulability (10). Individuals who have those coexisting conditions 
frequently have increased waist circumference and increased concentrations of 
CRP (91). 
Particularly during insulin resistance, an increased flux of free fatty acids 
from the periphery to the liver stimulates hepatic TG synthesis, which in turn, 
promotes the assembly and secretion of TG containing large VLDLs (92). When 
these larger VLDLs are lipolyzed by lipoprotein lipase, a population of LDL 
particles with changed apo B conformation is produced. These particles fail to 
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bind efficiently to LDL receptors and so have a prolonged residence time in the 
circulation. While these LDLs remain in the circulation, cholesteryl esters are 
replaced by TG by the action of CETP. TG rich LDL is a good substrate for 
hepatic lipase that finally generates sdLDL. The sdLDL particles are considered 
more atherogenic compared to the large buoyant ones due to the following 
reasons: 1) they have reduced affinity for LDL receptors (93); 2) they have 
greater binding capacity with endothelial glycoproteins that are heavily 
glycosylated (93); 3) they have greater tendency to penetrate the arterial 
intima(94); 4) they have reduced antioxidant defense, therefore, more readily 
oxidized by free radicals leading to modification of the apo B of LDL and rapid 
uptake by macrophage scavenger receptors (93).  
In a prospective study, the Quebec Cardiovascular
 
Study, the presence of 
sdLDL particles was associated with a 3.6-fold increase in the
 
risk of ischemic 
heart disease, independent of the other confounding variables like diabetes, 
medication use and systolic
 
blood pressure (89). At the 13-year follow up from 
the same study, concentrations of cholesterol
 
in the large LDL subfraction were 
not associated with
 
an increased CVD risk (95).  In fact, men with elevated 
cholesterol concentrations within large LDLs had a more favorable
 
CVD risk 
profile compared with individuals with low
 
cholesterol concentration in the large 
LDL subfraction; but the concentrations of cholesterol in the sdLDL subfraction 
were positively related to CHD events and risk (95). Similarly, another study done 
with healthy adults confirmed that, among men, the risk of developing CHD was 
significantly correlated with the amount of cholesterol in sdLDL particles after 
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adjusting for age, smoking, diabetes, BMI, SBP and LDL-C (96).  The correlation 
was not significant after adjustments of TG and HDL-C (96). In women, however, 
CHD development was not at all correlated with the concentrations of cholesterol 
in sdLDL particles (96). A large multi-ethnic cohort study done with healthy 
individuals found that small and large LDL particle concentrations were inversely 
correlated with each other, and when LDL subclass was taken into consideration, 
increased total LDL particle number was associated with increased carotid 
intimal-medial wall thickness (28). 
Several risk factors contribute to the presence of a pattern B phenotype, 
such as increased concentration of TG rich lipoproteins, low HDL-C, and 
increased hepatic lipase activity.  It has also been suggested that genetic 
background as well as race/ethnicity also contribute to LDL heterogeneity (81). A 
study that included Mexican Americans and Whites from the San Antonio, TX 
area reported significantly smaller LDL size in Mexican Americans predicting 
higher prevalence of LDL phenotype B in Mexican Americans than in non-
Hispanic Whites.  However, after adjusting for TG, glucose and insulin 
concentrations the difference was no longer statistically significant (97). Another 
study that included three ethnic groups; African Americans, Hispanics and non-
Hispanic Whites, showed the ethnic differences in LDL size after adjusting for 
confounding factors such as: obesity, body fat distribution, glucose levels and 
insulin sensitivity, with the greatest amount of sdLDL particles in Mexican 
Americans. However, after adjusting for TG and HDL-C the ethnic differences in 
LDL size diminished and it was no longer significant (98).  
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Although LDL heterogeneity appears to be a useful indicator of having 
CVD in presence of other CVD risk factors such as insulin resistance, obesity 
and/or dyslipidemia, there is scanty information about LDL phenotype and its 
association with CVD in Mexican Americans (81). Therefore there is a pressing 
need to conduct more research regarding LDL phenotype and its influence in 
CVD risk among Mexican Americans to derive more conclusive information in 
this population.   
HDL subfractions 
Similar to LDL particles, HDL particles are also categorized by their size; 
particles with various sizes play different roles in protection against CVD events. 
Clinical studies have often grouped HDL subfractions into large and sHDL on the 
basis of particle size and generally correspond to the HDL2 and HDL3 levels 
obtained through gradient gel electrophoresis (99). Studies have shown that the 
size and distribution of HDL particles are also associated with CVD risk. These 
studies reported that high HDL2 concentrations were protective against CVD risk 
(100-102). In a study with men who had a coronary angiography, age and HDL2 
were the strongest predictors of the degree of CVD; individuals without CVD had 
two times higher concentrations of HDL2 than those with CVD (100, 101). In the 
same study, a weak association was observed between the HDL3 and CVD risk. 
Another study also reported that men with HDL2 concentrations <25 mg/dL had 
four times greater risk of developing myocardial infarction than those with HDL2 
concentrations >39 mg/dL. Furthermore, men with HDL3 concentrations <15 
mg/dL had two times higher risk than those with HDL3 concentrations >19 g/dL 
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(101). In this study, even after controlling for other CVD related risk factors, 
HDL-C and HDL2 were still inversely correlated to myocardial infarction. 
Similarly, in another study investigating atherosclerosis related risk with 
improvement in HDL particle profile, the CAD progression decreased in 
quantitative coronary arteriography at six months period (102). In this study, the 
improvement in HDL particle profile was described by higher concentration of 
larger HDL particles and lower concentrations of sHDL particles. In contrast, in 
the Veterans Affairs HDL Intervention Trial (VAHIT), HDL2 particles did not 
predict the major CVD events, and it was concluded that increasing total HDL is 
more relevant against CVD risk (76). Nevertheless, not only the HDL cholesterol 
concentration, but also HDL particle size and the distribution of cholesterol 
among HDL particles have an important effect on CVD risk. A more protective 
effect can be achieved by increasing number of HDL2 particles and 
concentrations of apo A1 compared to their smaller counterparts (11).  
Overweight/Obesity 
Obesity has become a global epidemic, 68% of adults residing in the US 
(72% of men and 64% of women) are either overweight or obese (29). Over the 
10-year period from 1999 to 2008, the obesity prevalence increased from 28% in 
1999-2000 to 32% in 2007-2008 among men, and from 33% in 1999-2000 to 36% 
in 2007-2008 among women (30). In addition, there are disparities in the 
prevalence of overweight/obesity based on race/ethnicity. Among men, Mexican 
Americans have a greater prevalence of being overweight/obese (80%) than 
Whites (73%) and Blacks (69%); among women, Blacks (78%) and Mexican 
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Americans (77%) have a higher prevalence than Whites (61%) (30). If the rate of 
obesity continues to increase at a similar trend, by 2030 it could cost $861 to $957 
billion of healthcare costs, which would account for 16% to 18% of total US 
health expenditures (103).  
In the MESA study, which included participants from diverse ethnic 
backgrounds, excessive body weight was reported to be higher in White, African, 
and Hispanic Americans than in Chinese Americans; however a positive 
relationship between excessive body weight and CVD risk was reported even in 
Chinese Americans as in other ethnic groups despite of fewer Chinese Americans 
being overweight or obese (104). Also, in obese individuals, 17% had CAC and 
45% had increased carotid IMT compared with normal body size individuals 
(104).  
Among Mexican Americans, several reports suggest that sociocultural and 
acculturation-related factors also affect the likelihood of being overweight/obese. 
According to data from NHANES 1988-1994 that divided participants into three 
distinct groups: Mexico-born, the US-born Spanish-speaking, and the US-born 
English-speaking.  In this study, Mexico-born Mexican Americans (both men and 
women) had smaller waist circumference than their US-born counterparts (105). 
Moreover, some but not all of the differences in waist circumference were 
explained by differences in dietary habits and physical activity. The US-born 
English-speaking individuals had higher levels of education, lower levels of 
poverty and higher employment rates than other two groups; therefore, 
socioeconomic status, age and education  also contributed towards the differences 
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in the waist circumference among the groups (105). A study that included 2,420 
foreign-born Hispanic adults aged 18 years and older found obesity to be related 
with the length of residence in the US even after adjusting for other confounding 
factors such as smoking, physical inactivity, self-assessed health, and chronic 
conditions (106). The increase in obesity was attributed to increased acculturation 
and adoption of inactive lifestyles of the US.  
Body weight adequacy is often characterized based on the body mass 
index (BMI), defined as an individual’s weight (in kilograms) divided by height 
(in meter square).  Based on BMI categories, overweight is defined as a BMI of 
25 to 29.9 kg/m
2
, and obesity is defined as BMI >30 kg/m
2
. Other measurements 
to assess adiposity include percent body fat, waist circumference (WC), and 
waist-to-hip ratio (WHR).  These measurements have more predictive power for 
estimating adiposity compared to BMI (107). Some of the disadvantages of using 
BMI as a measure for adiposity are: (a) BMI does not account for the difference 
between fat and nonfat mass such as bone and muscle; (b) BMI does not account 
for the changes in body composition that occur with age; and (c) BMI does not 
account for the relation between obesity and the outcome being measured (108). 
A recent study of nearly 360,000 participants from nine European countries 
showed that both general obesity and abdominal adiposity were associated with 
risk of death and support the importance of WC or WHR in addition to BMI for 
assessing mortality risk (31).A significant positive association has been 
established between obesity and increased mortality caused by CVD, some 
cancers, diabetes or kidney disease (109).  
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Obesity is associated with increased prevalence of traditional CVD risk 
factors such as hypertension, hyperlipidemia, diabetes and novel risk factors like 
hsCRP concentrations (110). Moreover, obesity adversely affects the cardiac 
function through its influence on known
 
risk factors such as hypertension, glucose 
intolerance, type 2 diabetes mellitus, dyslipidemia, and obstructive sleep apnea 
(110). When adipose tissue accumulates
 
in excess amounts, numerous alterations 
occur in the cardiac structure
 
and function (110, 111), including left ventricular 
chamber dilation, left ventricular hypertrophy, concentric remodeling, concentric 
left ventricular hypertrophy and left atrial enlargement. These structural changes 
further alter the cardiac, systolic and diastolic functions resulting in greater 
cardiac load, lower peripheral resistance, increased heart rate, and increase arterial 
pressure, which further put overweight/obese people at increased risk of heart 
failure and arterial fibrillation (110, 111). Therefore, an excessive body weight is 
an independent risk factor for abnormalities of the heart as well as of the blood 
vessels, and it is associated with a variety of cardiac complications including 
coronary heart disease, heart failure, and sudden death because
 
of its impact on 
the cardiovascular system. 
Obesity has been demonstrated to be associated with insulin resistance 
(112). In the evaluation of obesity, it has become apparent that it is not only the 
magnitude of the increase in fat mass, but also the site of distribution that plays an 
important role for the development of insulin resistance, and that the intra-
abdominal fat has been found to be associated with the insulin resistance (113). A 
study done with 196 healthy individuals found that insulin resistance and obesity 
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attributed by intra-abdominal obesity was associated with atherogenic lipid 
profile: increased TG, TC, LDL-C and decreased HDL-C (113). In this study, 
individuals who had intra-abdominal fat and insulin resistant also had increased 
cholesterol concentrations in sdLDL fractions, whereas the cholesterol 
concentration was reduced in HDL fractions. Therefore, an abnormality in body 
fat distribution leads to the accumulation of intra-abdominal adiposity, which in 
turn is associated with the development of insulin resistance, followed by 
dyslipidemia. Intra-abdominal fat would therefore be a contributor to an adverse 
lipoprotein profile and, thus, cardiovascular risk. 
Insulin Resistance/Diabetes  
Insulin Resistance 
  Insulin is a hormone secreted by the beta-cells of the pancreas. The major 
role of insulin is to facilitate the transport of glucose into the cells and tissues 
(74). Insulin resistance occurs when the cells and tissues are unable to respond to 
and use insulin. It has been suggested that the decrease in glucose uptake that 
results from insulin resistance and the pancreas response by increasing insulin 
production (leading to hyperinsulinemia), which plays a vital role in the 
development of a variety of clinical syndromes such as obesity, hypertension and 
dyslipidemia, all of which increase CVD risk (77, 97, 114, 114, 115, 115, 116). At 
present, excess body weight and physical inactivity are thought to be the major 
risk factors for the development of insulin resistance. The association of obesity 
with insulin resistance and CVD risk is not only related to the degree of obesity 
but also seems to be critically dependent on body fat distribution (115). 
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Individuals with greater degrees of central adiposity develop CVD more 
frequently than do those with a peripheral body fat distribution (115). 
Furthermore, it has been observed that the decrease in glucose uptake mediated by 
insulin resistance leads to increased plasma insulin concentration, increased 
hepatic TG-rich VLDL secretion, and hypertriglyceridemia (114). The 
dyslipidemia commonly present in insulin resistance consists of 
hypertriglyceridemia and reduced HDL-C concentration, both of which contribute 
towards increased CVD risk. In addition, LDL is converted to smaller, denser 
particles (77). This dyslipidemia is often observed with the presence of pre-
diabetes (i.e. the individuals with insulin resistance but without diabetes) (97). 
Several factors are likely to be responsible for this type of dyslipidemia such as 
insulin effects on the liver, apoprotein production, regulation of lipoprotein lipase, 
actions of cholesteryl ester transfer protein (CETP), and peripheral actions of 
insulin on adipose and muscle (114).  
Insulin and Carbohydrate Metabolism 
Dietary carbohydrates are ultimately broken down in the small intestine 
into glucose, which is then absorbed into the blood. Elevated concentrations of 
glucose in the blood stimulate the release of insulin, a hormone that acts on cells 
and tissues to stimulate uptake, utilization and storage of glucose. The effects of 
insulin on glucose metabolism vary depending on the target tissue (74). Two 
important effects are:  
(a) Insulin facilitates entry of glucose into muscle, adipose and several other 
tissues. 
  41 
(b) Insulin stimulates the liver to store glucose in the form of glycogen. A large 
fraction of glucose absorbed from the small intestine is taken up by hepatocytes, 
which is converted and stored in the form of glycogen in the liver.  
Insulin and Lipid Metabolism 
The metabolic pathways for utilization of fats and carbohydrates are 
interrelated. Considering the important effects of insulin on carbohydrate 
metabolism, it can be assumed that insulin also has some important effects on 
lipid metabolism: 
(a) When the liver is saturated with glycogen, insulin promotes synthesis of fatty 
acids that are exported from the liver as TG in lipoproteins. TG are hydrolyzed in 
the circulation through the activity of lipoprotein lipase, providing free fatty acids 
for use in other tissues, including adipocytes, which use them to synthesize other 
TG (74, 114).  
(b) Insulin inhibits the breakdown of fat in adipose tissue by inhibiting the activity 
of intracellular lipase that hydrolyzes TG to release fatty acids (74, 114). 
Diabetes Mellitus 
The most prevalent form of diabetes mellitus, type 2 diabetes, is 
characterized by the combination of insulin resistance and defective secretion of 
insulin by the beta-cells of the pancreas (116). Clinically, type 2 diabetes is often 
diagnosed as fasting glucose >126 mg/dL and postprandial glucose (2 hr post 
glucose load) >200 mg/dL (117).   
As the United States population age, and with the increase in the 
prevalence of obesity and sedentary lifestyles, the prevalence of diabetes is also 
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increasing (1). Data from the Framingham Heart Study indicated that diabetes was 
increased from 5.4% in the earlier time period (1952-1974) to 8.7% in the later 
time period (1975-1998), despite a significant decline in hypertension, smoking, 
and elevated cholesterol (19). According to NHANES data from 2005-2008, 
about 18,300,000 adults residing in the US have diagnosed diabetes, about 
7,100,000 adults have undiagnosed diabetes, and the prevalence is slightly higher 
in women (8.3%) than in men (7.2%) (32). Among Mexican-American men, the 
prevalence of diagnosed diabetes was 1.7 times higher and the prevalence of 
undiagnosed was 1.6 times higher than that of their White counterparts. Similarly 
among women, the prevalence of diagnosed diabetes was 2 times higher among 
Mexican Americans than among Whites, with the prevalence of undiagnosed 
diabetes about similar in both ethnic groups (1). Furthermore, among the US adult 
population, the prevalence of prediabetes, characterized by fasting glucose 
between 100 and <126 mg/dL, is about 37% (81,500,000 adults) (32).  
About 65% of people with diabetes die from heart disease or stroke, and 
mortality rates related to heart disease among adults with diabetes are two-to-
four-times higher than the death rates for the adults without diabetes (32). On the 
basis of NHANES data between 1984 and 2004, the total prevalence of diabetes 
from 2005 to 2050, in the US, is expected to increase from 5.6% to 12%. The 
prevalence is expected to be increased by 99% among Whites, by 107% among 
Blacks, and by 127% among Hispanics (118). 
Data from a prospective study conducted in patients who had a myocardial 
infarction and no prior diagnosis of diabetes showed that one-third of individuals 
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actually had diabetes, which was diagnosed with a post-MI oral glucose tolerance 
test (119). Moreover, another third had either impaired fasting glucose or 
impaired glucose tolerance. Pre-diabetic individuals have an atherogenic pattern 
of risk factors such as hyperglycemia or hyperinsulinemia that further contributes 
towards the risk of developing CVD.  
Different ethnic groups are more likely to develop type 2 diabetes.  In the 
Hispanic Health and Nutrition Examination Survey (HHANES) 1982-1984, 
Mexican Americans and Puerto Ricans had significantly greater prevalence of 
diabetes than Cubans and Whites (31). In this study, Cuban adults were more 
educated and had higher income than Mexican and Puerto-Rican adults; they were 
also more likely to have smaller number of people per household than Puerto 
Ricans and Mexican Americans. These socioeconomic and environmental factors 
could be of importance to explain the differences in the prevalence of diabetes in 
these Hispanic groups. However, more recent data that compares the trends of 
prevalence of diabetes in these three Hispanic group is not available.  
Pathogenesis of CVD in Insulin Resistance/Diabetes   
Type 2 diabetes and insulin resistance often co-occur with other CVD risk 
factors including dyslipidemia and hypertension (116, 117). Individuals with 
diabetes are at
 
two-to-three-fold increased risk for CVD compared to those 
without diabetes (19). The pathogenesis of CVD in diabetes/insulin resistance is 
multifactorial and can be affected by metabolic factors, oxidation/glycoxidation, 
endothelial dysfunction and inflammation (19, 114). 
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Metabolic Disarrangements  
Metabolic disturbances associated with insulin resistance and diabetes 
include hyperglycemia and its derivatives, advanced glycation end products 
(AGEs), increased concentrations of free fatty acids, and lipoprotein alterations 
(19). These abnormalities are also found in individuals with the metabolic 
syndrome, formerly called insulin resistance syndrome (97).  
Similar to what is observed in with insulin resistance, lipoprotein 
abnormalities often observed in type 2 diabetes include elevated TG rich smaller 
VLDL particles and low concentration of HDL-C (114). LDL-C concentrations of 
diabetic individuals are similar to those without diabetes, but the particles are 
smaller, denser, and more atherogenic (120).  
The aforementioned metabolic changes in type 2 diabetes can result not 
only on a more atherogenic lipoprotein profile, but on altered cardiac function. 
This may result in part from the hypertension associated with diabetes/insulin 
resistance. Further, with the blockage in nerves and blood vessels done by 
atherosclerosis lesions, when the heart pumps blood the pressure of blood pushing 
against the walls of the arteries increases leading to high blood pressure (19). 
High blood pressure further strains the heart, damage blood vessels, and therefore 
increases the risk of heart attack (19).  
Oxidation/Glycoxidation 
Hyperglycemia increases oxidative stress and diminishes NO synthesis, 
which further leads to increased glycoxidation of circulating lipoproteins (121). In 
addition, hyperglycemia can result in the activation of protein kinase C, alter 
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insulin signaling, increase adhesion molecule gene expression on endothelial 
cells, and stimulate inflammation and smooth muscle cell proliferation (114, 121, 
122). 
Diabetes can lead to the generation of free radicals by glucose-dependent 
and -independent mechanisms. Auto-oxidation of glucose is known to generate 
oxygen-centered free radicals, and the cellular oxidation of glucose leads to 
generation of excess ROS in mitochondria (123).  Additionally, it has been proven 
that there is increased production of extracellular superoxide in monocytes from 
individuals with diabetes (123). Most molecules in the arterial wall can be 
modified by the spontaneous process of glycation, which is driven by 
hyperglycemia and is typically associated with oxidation in an irreversible process 
termed glycoxidation, through which proteins and lipids form advanced glycation 
end products (AGEs).  These complex substances are highly toxic to the integrity 
and function of the vessel walls (120, 122, 123). 
It has been demonstrated an increased susceptibility to oxidative 
modification of LDL in insulin resistance and diabetes, in part related to 
compositional changes, for example, the presence of sdLDL (97). Moreover, the 
increased generation of products of lipid peroxidation indicates an excess 
oxidative burden, which may be secondary to reduced antioxidant defenses (97). 
Oxidative stress can influence the expression of multiple genes in vascular cells 
that accelerates atherosclerosis (120). Evidence of oxidative damage has been 
demonstrated in arterial samples obtained from animal models of experimental 
diabetes and from human subjects with diabetes (124). 
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Endothelial Dysfunction 
Endothelial dysfunction is a shift of the actions of the endothelium toward 
reduced vasodilation, a proinflammatory state, and prothrombic properties (125). 
Endothelial dysfunction is an important early event in the pathogenesis of 
atherosclerosis, contributing to plaque initiation and progression (125). 
Endothelial dysfunction in diabetes is associated with atherosclerosis as it is 
accompanied by altered expression of adhesion molecules that affect thrombosis 
and increased permeability of oxidants and AGEs (122). Furthermore, there is 
evidence that there may be a discrete genetic determinant of endothelial 
dysfunction, as illustrated by studies of first-degree relatives of individuals with 
type 2 diabetes who manifest impaired endothelium dependent vasodilation in 
response to insulin (126). 
Insulin resistance promotes the release of free fatty acids from the liver; 
having elevated concentrations of plasma free fatty acids is harmful because of 
their effect on vascular cells (74, 97). Endothelial cells often utilize free fatty 
acids as a source of energy, but high levels of free fatty acids can lead to 
increased oxidative stress and diminished NO synthesis in those cells (19). 
Inflammation 
Inflammation is an essential immune response that enables survival during 
infection or injury and maintains tissue homeostasis under a variety of deleterious 
conditions (127). However, inflammation comes at the cost of a transient decline 
in tissue function, which can in turn contribute to the pathogenesis of diseases of 
altered homeostasis (127). Therefore, with insulin resistance/diabetes 
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inflammation not only contributes to acute cardiovascular events, but is also plays 
an important role in the initiation and progression of atherosclerosis (128). 
Several inflammatory markers have been identified in atherosclerotic lesions. 
Among them are cytokines and growth factors, which are released by activated 
macrophages (114). Cytokines increase the synthesis of platelet activating factor, 
stimulate lipolysis, markedly stimulate the expression of adhesion molecules, and 
up regulate the synthesis and cell surface expression of procoagulant activity in 
endothelial cells (128). Therefore, cytokines may play crucial roles not only in the 
initiation but also in the progression of atherosclerotic lesions. Another 
pathogenic phenomenon identified with insulin resistance/diabetes is increased 
formation of immune complexes (129). These immune complexes promote the 
release of tumor necrosis factor, which has been shown to up-regulate the 
synthesis of CRP (127). High concentrations of CRP have been demonstrated in 
individuals with insulin resistance, and the increase in immune complexes not 
only initiates and progress the process of atherosclerosis, but also contribute to 
plaque rupture and cardiovascular events (122, 129). 
C-reactive Protein 
Recognizing that an inflammation plays a key role in the pathogenesis of 
CVD led to the measurement of circulating inflammatory molecules such as C-
reactive protein (CRP). A marker of systemic inflammation, CRP is an acute 
phase reactant that increases during tissue injury or infection. It is synthesized 
primarily by the hepatocytes and is stimulated by interleukin (IL)-6 and other pro-
inflammatory cytokines (130). Hepatic production of CRP is increased by visceral 
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adipocyte mediated secretion of inflammatory cytokines (131). In various 
prospective studies, the level of circulating CRP has been measured by assessing 
high sensitivity C-reactive protein (hsCRP), a high sensitivity assay (130). 
Concentrations of hsCRP fluctuate in response to wide ranges of stimuli. For 
example, body weight, chronic as well as acute inflammation, and components of 
the metabolic syndrome are positively associated with hsCRP; whereas weight 
loss and increased activity are negatively associated with hsCRP (132). These 
associations have demonstrated the positive relationship of CRP with CVD risk 
factors making it as a useful component to estimate the CVD risk. Furthermore, 
CRP plays a vital role in the pathogenesis of atherosclerosis through several 
mechanisms: 1) it induces the expression of adhesion molecules by the 
endothelial cells, like intracellular adhesion molecule-1 (ICAM-1), vascular cell 
adhesion molecule-1 (VCAM-1) and E-selectin, which play an important role in 
the development of atherosclerosis by migrating monocytes and T-cells into the 
vessel wall; 2) it gradually lowers the production of NO by endothelial cells, 
which has a vasodilatory effects on the vascular wall; 3) it induces the release of 
interleukin-1 beta (IL-1 beta) and tumor necrosis factor alpha (TNF-alpha) by 
monocytes leading to the initiation of coagulation contributing to the pathogenesis 
of atherosclerosis by enhancing adhesion molecule expression, smooth cell 
proliferation and migration; 4) it induces apoptosis in human coronary vascular 
smooth muscle cells, thus promoting atherogenesis; 5) it also increases the 
susceptibility of endothelial cells to destruction by cell-lysis, a mechanism that 
could lead to plaque erosion or rupture and precipitate acute coronary syndrome; 
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6) it is linked to the enhanced generation of oxygen radicals by monocytes and 
neutrophils, thus promoting endothelial injury and development of atherosclerosis 
(133). 
CRP is increasingly being recognized as a contributor in the pathological 
process of several diseases, including CVD, and therefore it may be useful as an 
adjunct to other prognostic indicators (134). Concentration of hsCRP (a measure 
of CRP) less than 1 mg/L is considered to be low risk for CVD, 1-2.9 mg/L is 
considered to be moderate risk for CVD and greater than 3 mg/L is considered to 
be at high risk for CVD (21). There is growing evidence on ethnic variation in 
concentrations of CRP. A Canadian study that included 1,250 participants 
documented 2-4 times higher CRP concentrations in Aboriginals (4.25 mg/L) and 
South Asians (2.47 mg/L) than in Whites (1.95 mg/L) and Chinese (1.50 mg/L) 
(135). In this study, controlling for components of metabolic syndrome such as 
abdominal adiposity, BMI, TG, systolic blood pressure, glucose metabolism, 
HbA1c substantially reduced, although did not completely eliminate, the ethnic 
differences in CRP distribution. After controlling for components of metabolic 
syndrome and CVD the CRP concentrations decreased by 26% among 
Aboriginals, increased by 7% among South Asians, increased by 2% among 
Whites, and 55% among Chinese. 
Among US adults, NHANES 1999-2000 data suggested that the age-
adjusted CRP concentrations in Mexican-American and Black women was 55% 
and 41% higher than in their White counterparts; however CRP concentrations 
did not differ by race or ethnicity among men (20). In a cross-sectional study, 
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including 3,154 women, CRP concentrations were the highest in African-
American women (3.2 mg/L), followed by Hispanics (2.3 mg/L), Whites (1.5 
mg/L) and Asian women (0.6 mg/L) (136).  Having a BMI >30 kg/m
2
, was 
associated with a 6-fold increased risk of having CRP >3 mg/L. Moreover, there 
was a strong joint association between BMI and Waist to hip ratio (WHR) with 
CRP concentrations independent of age, SES, and ethnicity. In addition after 
adjustment for age and ethnicity, within each tertile of BMI, CRP concentrations 
increased with increasing WHR. Similarly, within each WHR tertile, higher CRP 
concentrations were observed as BMI increased (137).  
Although CRP appears to be a useful predictor of vascular disease in 
apparently healthy people, its general applicability to screening Mexican 
American or other ethnic populations who are at risk for CVD is currently 
debated because the majority of evaluations of CRP have been conducted among 
individuals of European origin (137). Therefore, there is a pressing need to 
conduct more research regarding hsCRP as a screening tool for CVD risk among 
the Mexican-American population.   
Genetic Predisposition  
Genetic predisposition is often expressed as heredity. Heredity means 
parents passing their characteristics like eye color, hair color, age at onset of 
menopause, age at onset of chronic diseases, cognitive functioning in older age, 
etc. to their offspring(s) via genes (138), (139, 140). A gene is a fundamental 
chemical unit that carries a segment of deoxyribonucleic acid (DNA) coded with 
hereditary information (140). It further determines the genotype, the characteristic 
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a human may develop throughout their life based on information imprinted in the 
genes. But the characteristic that actually develops in a human is called a 
phenotype, which heavily depends upon the complex interaction between genes 
and their environment.  
The genetic history of the family has been predicted as an independent and 
non-modifiable risk factor for heart disease. Therefore, the genetic predisposition 
now has been recognized as a novel approach for understanding cardiovascular 
inheritances (141). It has been understood that the development of CVD is due to 
a complex interaction between environment and genetics. The relative 
contribution of these factors to the development of disease and the manifestation 
of symptoms also differs between individuals. Furthermore, genes have been 
identified for the particular chronic disease but the challenge is to identify the 
genetic components and the environments in which they are expressed, increasing 
the complexity of the disease. 
Current studies have started interpreting CVD pathways by the mutation 
of a large number of genes instead of the more traditional focus on single gene 
variants (142).  A prospective genome study that followed a cohort of White 
female health professionals, initially free of chronic diseases, for 10.2 years 
confirmed the incremental contribution of genetic variation at a chromosome 
(9p21.3) towards the future CVD events (142). However, this genetic variation 
only marginally contributed towards the prediction of future CVD risk, and no 
independent correlation was observed between this genetic variation and 
traditional risk factors or inflammatory markers (hsCRP). Similarly, a 
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longitudinal study with middle-age men, free from family history of heart disease 
and conventional risk factors used in the Framingham Risk algorithm, confirmed 
that variation in the chromosome 9p21.3 was strongly associated but was not 
statistically significant with CHD risk after a 15 year follow-up (143).  However, 
the addition of a second and a third single nucleotide polymorphism (SNPs) 
increased the CHD risk prediction by 8.4% and 13.3%. This observation foresees 
that a single genotype may not be able to predict the multifactorial heart disease 
on its own, but when it comes together with other SNPs, that have similar allele 
frequency, the risk prediction can be improved significantly.  
Among 644 Mexican-American adults participating in the San Antonio 
Family Heart Study, a significant linkage between HOMA-IR and chromosome 
12q24 has been reported (144). This is a region that shelters several candidate 
genes related to obesity and diabetes (144). In a study with Japanese youth, the 
mutation of genes residing in this location has been identified as a responsible 
factor for the onset of premature diabetes (145). There is a possibility that the 
chromosome 12q24 region could also possess an importance in relation to 
diabetes and other important CVD risk related phenotypes in Mexican Americans. 
Gene–environment interactions have been believed to be one of the 
important factors for determining CVD risk (140). Genes produce their effects via 
proteins in an indirect way and the ultimate outcome of gene action may vary for 
different environments (140). Although genes do not change over the life 
progression, their characteristics can be modified in response to the change in the 
environment (140). A Twin study done with 157 adult monozygotic White twins, 
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reared apart or together, confirmed that plasma lipid and lipoprotein 
concentrations were found to be highly heritable, whereas waist-circumference, 
insulin resistance, plasma glucose, insulin and blood pressure were found to be 
moderately heritable (146). When the data was analyzed for metabolic syndrome 
components, waist-circumference and plasma glucose were primarily influenced 
by both genetic factors and environmental factors (such as parents, siblings, 
home, and economic factors). This indicates that these two CVD components may 
be affected by a variety of influences in addition to insulin resistance. Together 
the results proposed that genes play a dominant role in the development of CVD 
risk and that there are common genetic and environmental influences that affect 
certain CVD components, leading to the development of metabolic syndrome.  
In the Mexican American population, genetic influence on phenotypes 
such as BMI, waist circumference, percent body fat, WHR, fasting glucose, 
fasting insulin, blood pressure, etc. has been documented (147). A study with 42 
extended family members of Mexican Americans confirmed the contribution of 
both genetic
 
and environmental influences to a large panel of CVD
 
risk factors, 
such as serum lipids, lipoproteins,
 
glucose, hormones, adiposity, and blood 
pressure (147). In this study, for the lipid and lipoprotein phenotypes,
 
environmental covariates such as age, gender, etc. accounted for <15% of the total 
phenotypic variation, whereas
 
genes accounted for 30% to 45%.
 
Similarly, genes 
also accounted for 15% to 30% of the phenotypic
 
variation of glucose, hormones, 
adiposity, and blood
 
pressure. This raises the question whether Mexican 
Americans have certain non-modifiable genetic predisposition that in combination 
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with environmental influences could lead to CVD and other chronic diseases. 
Therefore, a future advancement in CVD genetics has to rely on the ability to 
understand multiple SNPs that have similar allele frequencies and the gene-
environment interaction rather than on single gene-focused research. 
Figure 1: Lipoprotein Metabolism 
.  
 
Abbreviations: A, apoprotein A; B, apoprotein B; C apoprotein C; CE, cholestryl 
ester; CETP, cholestryl ester transfer protein; Chol, cholesterol; E, apoprotein E; 
HDL, high-density lipoprotein; IDL, intermediate-density lipoprotein; LCAT, 
lecithin-cholesterol acyltransferase; LPL, lipoprotein lipase; LDL-R, low density 
lipoprotein receptor; LDL, low density lipoprotein; TG, triglyceride; VLDL, very-
low-density lipoprotein. 
  55 
CHAPTER 3 
MATERIALS AND METHODS 
The present study was conducted in a sub-sample of Maricopa County 
Insulin Resistance Initiative participants to evaluate CVD risk factors among 
Mexican Americans residing in the Phoenix metropolitan area. Participants had 
already been recruited as a part of the Health Research Alliance Arizona / Arizona 
Insulin Resistance Registry, and their blood samples had been collected. The 
present study used one of the aliquots of archived serum for the measurement of a 
complete lipid panel (TC, LDL-C, HDL-C and TG), hsCRP (as a biomarker of 
inflammation), and the distribution of cholesterol in LDL and HDL particles. In 
this section the Maricopa County Insulin Resistance Initiative will be described 
first, followed by the protocol for the proposed sub-study. 
Maricopa County Insulin Resistance Initiative Protocol 
The Health Research Alliance Arizona / Arizona Insulin Resistance 
Registry was developed with the purpose of creating a HIPAA compliant, 
biomedical informatics driven database of individuals who could participate in 
clinical research in the area of the metabolic syndrome. The goal is to develop a 
database of more than 1000 individuals who are representative of the service base 
of the Health Research Alliance Arizona / Arizona Insulin Resistance Registry 
and the surrounding communities. Participants were screened for components of 
the metabolic syndrome, and they donated additional serum, RNA, and DNA 
samples for a specimen bank.  The study was been approved by the Institutional 
Review Board at Arizona State University [Appendix A]. 
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Subjects: Participants recruited for the Health Research Alliance Arizona / 
Arizona Insulin Resistance Registry include individuals self-identified as Latino 
or Mexican-American, 12 to 65 years old, who have never been diagnosed with 
insulin resistance or diabetes i.e. participants self-reported being free of diabetes 
and those who were found to meet the criteria for diabetes diagnosis were 
unaware of having it. Also, at the time of recruitment none of the participants in 
the study were taking medications for diabetes. Whenever a participant was 
identified to meet the diagnostic criteria for diabetes at the time of participation 
they were suggested to contact a physician to follow up and confirm the 
diagnosis. 
Recruitment: Participants were recruited through the Health Research 
Alliance Arizona / Arizona Insulin Resistance Registry clinics as well as 
community clinics and other organizations providing services to the Hispanic 
community, and through advertisements in Spanish language media.  
Informed Consent:  After receiving a thorough explanation of the study 
purpose and procedures and allowing time to answer questions, all participants 
gave written consent to participate.  Participants were given the option to consent 
to donate an additional blood sample for the creation of a serum, DNA and RNA 
bank.  Consent forms were available in English and Spanish [Appendices B and 
C]. 
Study Protocol: Participants, who had been fasting at least eight hours 
overnight, completed a short medical history questionnaire, after which height and 
weight, waist and hip circumferences, blood pressure and body composition were 
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measured.  Body composition was measured using a bioelectrical impedance 
analyzer (BIA- 310e; Biodynamics, Seattle, WA). A urine sample was collected 
from each participant for the analysis of microalbumin. An intravenous line was 
then placed in the arm for blood drawing purposes and a fasting blood sample was 
obtained (20 ml) for measurement of glucose, insulin, serum lipids, HbA1c, blood 
chemistry and a complete blood count.  An extra 21 mL of blood were collected 
from the participants who consented for sample archiving for the creation of a 
serum, DNA and RNA bank.  An oral glucose tolerance test was then performed 
using a standard 75g glucose solution, with blood collected at times -30, -15,  -5, 
0, 30, 60, 90 and 120 minutes (2 ml each).  
Samples were sent to a Clinical Laboratory Improvement Amendments 
(CLIA) certified laboratory (Sonora Quest, Phoenix, AZ) for the measurement of 
glucose, lipids, blood chemistry, blood count and HbA1c. A study physician 
interpreted the blood parameter values, and the participants were reported with 
their results.  Participants who had abnormal blood glucose profile and/or other 
metabolic abnormality were suggested to contact a physician for appropriate care.  
Serum insulin concentrations were determined using an enzyme 
immunoassay (ALPCO Diagnostics, Salem, NH).  Serum glucose was measured 
using a YSI 2300 Stat Plus glucose and lactate analyzer (YSI Incorporated Life 
Sciences, Yellow Springs, OH). DNA and RNA were isolated and purified using 
PAXgene blood DNA and RNA systems, respectively (PreAnalytiX, Franklin 
Lakes, NJ).   
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Present Study Protocol 
Materials: Reagents for measuring TC, LDL-C, HDL-C, TG and hsCRP 
as well as deionized water were purchased from Roche Diagnostics (Indianapolis, 
IN). The LDL and HDL electrophoresis kits containing LDL and HDL gel tubes, 
loading gels, and buffer salts (tris aminomethane 66.1 g/100 g, boric acid 33.9 
g/100 g, pH 8.2 - 8.6) were purchased from Quantrimetrix Corporation (Redondo 
Beach, CA). 
Samples: Analyses for the present study were done using one aliquot (500 
l) of archived serum from eighty overweight/ obese participants selected from 
the Health Research Alliance Arizona / Arizona Insulin Resistance Registry.  
Selected samples were from participants who were 30 to 65 years old, who self-
reported being free of insulin resistance or diabetes and had self-identified as 
Latino or Mexican American. Participants who met the criteria of hyperglycemia 
or diabetes diagnosis were unaware of having it. The age criteria was used for the 
participants in order to meet the requirements of using the Framingham risk score 
to calculate 10-year CVD risk.  
Sample selection was conducted systematically using SPSS 17.0 for 
Windows (SPSS Inc., Chicago, IL) as follows. Of the 399 participants in the 
Maricopa Insulin Resistance Registry, only participants who were 30 years and 
older and were overweight and obese (BMI>25kg/m
2
) considered for the present 
study. Participants who met those inclusion criteria were stratified in the database 
according to their TG, HDL-C and glucose concentrations and were further 
divided into four different sub-groups depending upon their diabetic dyslipidemia 
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(low HDL-C and high TG) status as well as varying degree of hyperglycemia. For 
example: first group had healthy participants with normal lipid and glycemic 
profiles (NC); second group had normodyslipidemic-normoglygemic participants 
(DN) defined by high TG (>150 mg/dL) and low HDL (<40 mg/dL for men and 
<50 mg/dL for female) but normal glycemic profile; third group had 
dyslipidemic-prediabetic participants (DPD) defined by high TG and low HDL 
accompanied by IGT and/or IFG; and fourth group had dyslipidemic-diabetic 
participants (DD) defined by high TG and low HDL accompanied by type 2 
diabetes. After separating the participants in four different groups, we randomly 
selected one aliquot of archived serum samples of 20 participants from each 
groups i.e. 20 from NC group; 20 from DN group; 20 from DPD group; and 20 
from DD group, for a total sample size of 80. No additional blood was drawn 
from study participants for purposes of this study. The samples were transported 
from the Clinical Research Unit (Tempe Campus, ASU) to the Nutrition 
laboratory (Polytechnic East Campus, ASU) following a protocol approved by the 
Institutional Biosafety Committee at Arizona State University [Appendix D]. 
Methods: A complete lipid panel (TC, LDL-C, HDL-C and TG) was 
measured in serum with colorimetric enzymatic assays using an automated 
chemistry analyzer (Cobas C111; Roche Diagnostics, Indianapolis, IN). Serum 
hsCRP was measured using a turbidimetric assay using an automated chemistry 
analyzer (Cobas C111; Roche Diagnostics, Indianapolis, IN).  The automated 
chemistry analyzer was calibrated and tested for quality control for each analysis. 
For the reliability of the process, quality control tests were run for each assay 
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before the samples were analyzed. For the validity, the serum samples were 
analyzed in triplicates; for a given sample if the concentrations of parameter(s) 
analyzed were out of range or the concentrations achieved in triplicates differ 
drastically then the sample(s) was reanalyzed for that parameter(s).  
LDL and HDL particles were separated by polyacrylamide tube gel 
electrophoresis using the Lipoprint system (Quantimetrix Co., Redondo Beach, 
CA) followed by densitometric quantification of cholesterol in each of the 
lipoprotein subfractions as described below. Density of the bands containing 
lipoproteins of different sizes was quantified after densitometry scanning using 
Lipoware software (Quantimetrix Co., Redondo Beach, CA).  
Quantimetrix Lipoprint LDL System. Briefly, 25 L of sample and 200 L 
of loading liquid gel were loaded onto precast linear polyacrylamide gel (stacking 
gel and separating gel) tubes. After mixing, the acrylamide loading gel was 
photopolymerized for 30 minutes in the presence of fluorescent light, at room 
temperature. Samples were electrophoresed for 60 minutes using a current of 
3mA/ tube, in a chamber containing the running buffer solution (tris 
aminomethane 66.1 g/100 g, boric acid 33.9 g/100 g, pH 8.2 - 8.6). Tubes were 
scanned for computer assisted data analysis using Lipoware LDL Research Use 
software (Quantimetrix Co., Redondo Beach, CA). 
  Quantimetrix Lipoprint HDL System. Briefly, 25 L of sample and 300 L 
of loading liquid gel were loaded onto precast linear polyacrylamide gel (stacking 
gel and separating gel) tubes. After mixing, the acrylamide loading gel was 
photopolymerized for 30-45 minutes in the presence of fluorescent light, at room 
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temperature. Samples were electrophoresed for 50 minutes using a current of 
3mA/ tube, in a chamber containing the running buffer solution (tris 
aminomethane 66.1 g/100 g, boric acid 33.9 g/100 g, pH 8.2 – 8.6). Tubes were 
scanned for computer assisted data analysis using Lipoware HDL Research Use 
software (Quantimetrix Co., Redondo Beach, CA). 
 While analyzing both LDL and HDL subfractions, the analyses 
conducted were tested for reliability and validity. Quality controls were run before 
analyzing the serum samples to check reliability. Similarly, if the analyses 
showed an abnormal result then that sample was reanalyzed for the validity.  
 Insulin was measured in serum samples with a chemiluminescence 
solid-phase immunometric assay using an automated immunoassay analyzer 
(Immulite; Siemens Healthcare Diagnostics Inc., Deerfield, IL). The automated 
immunoassay analyzer was calibrated and was tested for quality control. The 
working principle of this analyzer is that the sample and reagent are incubated 
together with the coated beads for 60 minutes. During this time, insulin in the 
sample forms the antibody sandwich complex. Unbound patient sample and 
enzyme conjugate are then removed by centrifugal washes. Lastly, a 
chemiluminescent substrate is added to the test unit containing the bead and the 
signal is generated in proportion to the bound enzyme. For the reliability of this 
test, quality controls were run before analyzing the serum samples. And for the 
validity, if the analyses showed an abnormal result then that sample was 
reanalyzed.  
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 Calculation of Framingham and HOMA Score: Cardiovascular disease 
risk was calculated using the Framingham score (148).  This simplified coronary 
heart disease prediction algorithm was built using blood pressure and cholesterol 
categories defined by the Joint National Committee on Blood Pressure and the 
National Cholesterol Education Program, and was designed in a community-based 
cohort setting (Framingham Heart Study) that included more than 5,000 people 
followed for 12 years (148). The algorithm uses age, TC or LDL-C, HDL-C, 
blood pressure, diabetes and smoking for the prediction of coronary heart disease 
risk. A gender-specific algorithm with LDL-C categories was used to calculate the 
individual 10-year probability of developing coronary heart disease. 
  Insulin sensitivity was assessed by calculating the homeostatic model 
assessment (HOMA) score (149, 150). HOMA was calculated according to the 
following formula: HOMA = glucose (mM) x insulin (μU/ml)/22.5. Glucose 
values measured in the Maricopa County Insulin Resistance Initiative Study were 
used for the assessment. 
Statistical Analysis:  Statistical analyses were conducted using SPSS 17.0 
for Windows (SPSS Inc., Chicago, IL). Data were summarized using descriptive 
statistics (mean and standard deviation). Descriptive data are provided in tables. 
Data were explored for normality and if needed were log/inverse transformed to 
achieve normality and so indicated in the tables. A correlation analysis was used 
to explore the relationship between the independent CVD risk factors including 
LDL-C, TG, HDL-C, hsCRP and cholesterol in sdLDL particles, with CVD 
Framingham risk score. A correlation analysis was used to explore the association 
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between total cholesterol in sdLDL particles and insulin resistance assessed using 
the HOMA score.  
A one-way analysis of variance (ANOVA) was used to test the differences 
in LDL-C, HDL-C, hsCRP, cholesterol in LDL and HDL particles, and 
cholesterol and HDL-C  in HDL subfractions among participants classified as 
normolipidemic-normoglycemic-controls, dyslipidemic-normoglycemic, 
dyslipidemic-prediabetic, and dyslipidemic-diabetic. Dunnett’s T3 post-hoc test 
was used for the parameters that were not homogenous (fasting glucose, 2-hr 
glucose, HDL, TG, hsCRP and diastolic blood pressure) and Tukey’s post-hoc 
test was used for rest of the parameters to find differences between means in pair-
wise comparisons. Fasting glucose, HbA1c, TG, % 10-yr CVD risk, mean LDL 
size, mean LDL size, and % cholesterol in intermediate HDL particles, HDL 
cholesterol, hsCRP, % of cholesterol in the sdLDL particles, insulin and HOMA-
score were non-normally distributed. The one-way ANOVA assumes normality; 
therefore it was necessary to use a natural log/inverse transformation for the data 
prior to using the statistical analyses. When normality was not achieved even after 
transformations (fasting glucose, HbA1c, TG, % 10-yr CVD risk, mean LDL size, 
mean LDL size and mean LDL peak, and % cholesterol in intermediate HDL 
particles), variables were analyzed using a non-parametric Kruskal-Wallis test for 
the differences. Further Mann-Whitney, non-parametric t-test, was used to find 
the differences between means in each pair-wise comparison. Analyses were 
conducted at the 0.05 alpha level. 
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The bivariate Pearson correlation also assumes normality; therefore it was 
necessary to use a natural log/inverse transformation for the data prior to using the 
statistical analyses. When normality was not achieved after transformation 
(fasting glucose, TG, mean LDL size, mean LDL peak, % of cholesterol in the 
larger LDL particles, % of cholesterol in intermediate HDL particles and the 10-
year CVD risk) variables were analyzed using non-parametric Spearman’s 
correlation. 
Sample Size Calculation: A preliminary cross-sectional study in adults 
with normal controls and diabetics provided data for sample size calculation 
(151). They reported that controls had 11.8% ( 10.1) of LDL and diabetics had 
23.4% ( 14.4) cholesterol in sdLDL particles. This represents 98% higher 
amount of cholesterol in sdLDL particles in participants with diabetes. We 
anticipated the difference would be smaller in people with prediabetes. Therefore, 
we estimated to detect the difference as large as 30% we would need 20 
participants per group. The alpha level was set at 0.05 and beta error level at 0.2 
(i.e. a power of 80% to detect a difference as large as 30%). 




Table 1 shows the descriptive characteristics of study participants divided 
into the four different groups: normolipidemic/normoglycemic controls (NC), 
dyslipidemic/normoglycemic (DN), dyslipidemic/prediabetic (DPD), and 
dyslipidemic/diabetic (DD). Mean age was 41.6±7.8 years. Participants in the DD 
group were the oldest (45.1±8.6 years), and were significantly older than 
participants in the DN group (38.7±8.1 years; p=0.035). Per study inclusion 
criteria, all participants were either overweight or obese to minimize confounding 
due to adiposity.  Mean BMI was 32.2±7.1 kg/m
2
, and no significant differences 
were observed for BMI among the groups (p=0.664). Out of 80 participants, 65% 
were females and 35% were males. There were significantly more female 
participants in the NC and the DD groups (70%) than in the DN and DPD groups 
(60%; p=0.007). Regarding smoking, a large majority of the study participants 
self-identified as non-smokers, with significantly fewer smokers in the DPD 
group (15%) than in the other groups (20% for all other groups; p<0.0001). 
The prediabetes or diabetes was defined based on fasting glucose values 
and/or oral glucose tolerance test results.  Prediabetes was defined as a) impaired 
fasting glucose (IFG; fasting glucose >100 mg/dL but <126 mg/dL), b) impaired 
glucose tolerance (IGT; 2-hr glucose >140 mg/dL but <199 mg/dL), or c) both.  
In the DPD group (Figure 2A), 15% of participants had IFG, 10% had IGT and 
75% had both. Diabetes was defined as hyperglycemia after a 2-hr glucose 
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tolerance test (2-hr glucose > 200 mg/dL) regardless of fasting glucose 
concentrations.  Participants with diabetes were also stratified based on fasting 
glucose concentrations as follows: a) fasting normoglycemia (NG; fasting glucose 
< 100 mg/dL), b) impaired fasting glucose (IFG; fasting glucose >100 mg/dL but 
<126 mg/dL), or c) fasting hyperglycemia (FHG; fasting glucose >126 mg/dL). In 
the DD group (Figure 2B), in addition to hyperglycemia after a 2-hr glucose 
tolerance test, 20% of participants had fasting normoglycemia, 35% had impaired 
fasting glucose, and 45% had fasting hyperglycemia. 
Cardiometabolic Disease Risk Factors 
 The cardiometabolic disease risk factors of study participants are 
displayed in Table 2. As expected, participants in the DD group had the highest 
and the NC group had the lowest fasting glucose concentration (140.1+60.5 
mg/dL and 83.1 + 6.6,
  
respectively); fasting glucose was significantly higher in 
DD participants relative to the other groups (p<0.0001).  Fasting glucose was 
69% greater in DD, 12% greater in DPD, and 7% greater in DN participants than 
those in the NC group. For 2-hr glucose, participants in DD group had 168% and 
136% higher fasting glucose (259.4+53.5 mg/dL) than participants  in the NC 
(96.7+15.8 mg/dL) and DN (110.0+14.6 mg/dL) groups, respectively (p<0.0001). 
Relative to NC and DN participants, DPD  participants (155.6 + 23.0 mg/dL) had 
70% and 42% higher concentrations of 2-hr glucose, respectively (p<0.0001). 
This explains the insufficiency and/or insensitivity of insulin to clear glucose 
from the bloodstream in the presence of increasing insulin resistance.  For HbA1c, 
DD participants had 36%, 29% 33% higher HbA1c values than NC, DN and DPD 
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participants (7.5+2.2 vs. 5.5+0.2, 5.6+0.32, 5.8+0.3), and DPD participants had 
5.5% higher HbA1c values than NC participants with no differences between NC 
and DN participants. The differences were statistically significant (p<0.0001). No 
significant differences in insulin concentrations were observed among the groups. 
However, as predicted, the DD (14.6 + 6.4 mg/dL) and DPD groups (12.2 + 7.4 
mg/dL) had higher concentrations of insulin compared to the NC (9.9 + 10.4 
mg/dL) and DN groups (11.7 + 7.6 mg/dL). As shown in Figure 3, HOMA score 
was 133%, 88% and 75% higher in the DD group (4.9 + 2.8) compared to the NC, 
DN and DPD groups (2.1 + 2.2, 2.6 + 1.8 and 2.8 + 1.8, respectively; p=0.001). 
Blood pressures, systolic and diastolic, were significantly different among the 
groups (systolic p=0.036; diastolic p=0.044; Table 2). Systolic blood pressure was 
12% higher in DD group (130.5+21.1 mm Hg) than the NC group (116.3+18.1 
mm Hg), with no difference between DN (118.2+12.0 mm Hg) and DPD 
(127.6+19.3 mm Hg) groups. Similarly, diastolic pressure was 10% higher in the 
DD group (82.4+7.5 mm Hg) than in the NC group (74.9+7.6 mm Hg), with no 
differences in the DN (77.7+10.3 mm Hg) and DPD groups (81.9+12.1 mm Hg). 
HDL-C was negatively correlated with FG and 2-hr glucose (r= -0.38, p= 0.001; 
r= -0.29, p=0.013; respectively), and LDL-C was positively correlated with FG 
and 2-hr glucose (r= 0.26, p= 0.02; r= 0.37, p=0.001, respectively), as shown in 
Table 3. 
Fasting serum lipids and hsCRP concentrations are shown in Table 2.  
Individuals in the NC group (165.3 + 29.8 mg/dL) had the lowest and individuals 
in DD group (215.8 + 40.6 mg/dL) had the highest TC concentration (p<0.0001); 
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individuals in the DD group had 30% more TC than those in the NC group. There 
was a gradual increase in TC concentrations among individuals with increasing 
degree of hyperglycemia (NC, DN, DPD and DD had 165.4+29.8 mg/dL, 
183.0+26.1 mg/dL, 198.5+37.0 mg/dL, and 215.8+40.6 mg/dL, respectively; 
p<0.0001). LDL-C concentration was 27% and 12% higher in the DPD 
(121.3+30.0 mg/dL) compared to the NC (95.7 + 25.7 mg/dL),  and DN groups 
(108.5+24.3 mg/dL), respectively (p=0.013). Similarly, DD (123.1+35.8 mg/dL) 
had 29% and 13% higher LDL-C concentrations  than the NC (95.7+25.7 mg/dL) 
and DN groups (108.5+24.3 mg/dL), respectively (p=0.013). As per study design, 
HDL-C (47.8+13.3 mg/dL; p<0.01) was the highest and TG (90.7 + 32.3 mg/dL; 
p<0.01) was the lowest in the NC group compared to the other three groups. 
Interestingly, the DD group (3.5+2.1 mg/dL) had the lowest concentration of 
hsCRP relative to the other groups. However, concentrations of hsCRP were not 
significantly different among groups (p=0.683).  
There was a significant increase in % 10-year CVD risk with increasing 
degree of hyperglycemia (p<0.0001), as shown in Figure 4. Percent 10-year CVD 
risk in DD participants (10.0+9.0 %) was roughly three times greater than risk in 
NC and DN participants (2.7+2.9 % and 3.1+2.2 %, respectively; p<0.0001).  
Percent 10-year CVD risk in DD participants was 1.8 times greater than risk in 
DPD participants (5.6+5.6 %; p<0.0001). Similarly, DPD participants had two 
times greater 10-year CVD risk than NC participants, which was statistically 
significant.  
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LDL and HDL Phenotypes 
 As illustrated in Table 4 and Figure 5, NC participants had significantly 
less TC in the sdLDL particles (0.6±1.2% of TC; p<0.0001) than all dyslipidemic 
individuals, regardless of their hyperglycemic status (4.0±3.2%, 6.0±6.0%, and 
4.9±3.3%, respectively for DN, DPD and DD participants). Accordingly, as 
shown in Table 4, NC individuals had significantly larger LDL particles (mean 
diameter = 272.7±3.0 Å; p<0.0001), than dyslipidemic individuals (mean 
diameter = 266.1±4.0 Å, 265.1±6.0 Å, and 264.2±6.3 Å, respectively for DN, 
DPD and DD participants). LDL particles were 2.5% larger, 3% larger and 3.4% 
larger in NC group than those in DN, DPD and DD groups. 
In-depth illustrations of HDL subfractions are provided in Table 5 and 
Figure 6.  Dyslipidemic participants, irrespective of their prediabetes or diabetes 
status, had a lower proportion of HDL-C in the larger HDL particles than their 
NC counterparts (28.7±9.1% vs. 19.4±7.1%, 18.4±6.2% and 16.8±6.1%, for NC 
vs. DN, DPD and DD, respectively; p<0.0001). NC participants had significantly 
more HDL-C in the larger HDL particles than the other groups, whereas those 
with prediabetes had significantly more HDL-C in the sHDL particles (15.9±5.2% 
vs. 22.5±10% and 26.8±9.1%, respectively for NC, DPD and DD; p=0.001). 
Further, like HDL-C, the TC was also distributed differently in HDL subfractions. 
NC participants had significantly more TC in larger and intermediate HDL 
particles than participants in other groups (8.7+4.2% vs. 3.3+1.8%, 2.9+1.03%, 
2.6+3.5%, and 15.5+5.8% vs. 9.5+1.9%, 9.6+2.4%, 8.8+2.7%), respectively. 
However, NC participants (4.5+1.4%) had significantly more TC and DN 
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participants (3.4+1.0%) had significantly less cholesterol in sHDL particles with 
no differences in DN and DPD participants (3.5+1.3%, 4.0+1.0%; p=0.023). 
Relationship between CVD Risk Factors and 10-year CVD Estimates 
 Although the 10-year CVD risk was either positively or negatively 
correlated with all the lipid parameters, the results of statistical analyses of HDL-
C and LDL-C with the 10-year CVD estimates were not determined because the 
10-year CVD risk estimation was based on these variables. The relationship 
between CVD risk factors and % 10-year CVD risk, as determined by correlation 
analysis, is provided in Table 3 and Table 4. Serum concentrations of TG and TC 
were positively correlated with the 10-year CVD risk (r=0.384, p<0.0001 and 
r=0.340, p<0.05, respectively). The distribution of cholesterol in sdLDL particles 
was positively correlated with % 10-year CVD risk (r=0.247; p<0.05) and the 
distribution of cholesterol in intermediate and larger HDL-C was negatively 
correlated with % 10-year CVD risk (r=-0.38, p=0.001; r=0.34, p=0.002, 
respectively). However, no significant correlation between hsCRP and % 10-year 
CVD risk was found (r=0.08; p=0.478). Further, the ratio of TC and HDL-C 
(TC/HDL) was positively correlated with % 10-year CVD risk, TC in sdLDL 
particles and HDL-C in sHDL particles (r=0.404, p<0.0001; r=0.698, p<0.0001; 
r=0.602, p<0.0001) respectively. A negative association was also obtained 
between the TC/HDL and percentage of the cholesterol in sHDL, intermediate 
and large HDL particles (r=-0.35, p=0.002; r=-0.91, p<0.0001; r=-0.84, 
p<0.0001), respectively. Similarly, a negative association was obtained between 
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the TC/HDL a percentage of HDL-C in the larger HDL particles, (r=-0.562, 
p<0.0001). 


























































































Data shown as mean ± SD or %; values with different superscripts are 
significantly different  
2
NC: Normoglycemic normolipidemic Controls; DN: Dyslipidemic 
Normoglycemic; DPD: Dyslipidemic Prediabetic; DD: Dyslipidemic 
Diabetic 
3Criteria for defining Dyslipidemia = ↓ HDL and ↑ TG; Criteria for 
defining Prediabetic = IFG (fasting glucose >100-126 mg/dL) and/or 
IGT (2-hr glucose level >140-<200 mg/dL after 75g oral glucose 
tolerance test); Criteria for defining Diabetic = 2-hr glucose level >200 
mg/dL, after 75g oral glucose tolerance test 
4
One-way ANOVA was used to test the differences, and Tukey’s post-
hoc was used to find differences between means in pair-wise 
comparisons 
5
CHI non-parametric was used to test the differences in the variable 
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Data shown as % (n) of participants in DIR group 
Impaired fasting glucose (IFG): >100 - <126 mg/dL 
Impaired glucose tolerance (IGT): >140 - <199 mg/dL 
1
Diabetic: Glucose level >200mg/dL after 2-hr oral glucose 
(75g) tolerance test; data shown as % (n) of participants in DD 
group 
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Data shown as mean±SD; values with different superscripts are 
significantly different. 
2
NC: Normoglycemic Normolipidemic Controls; 
DN: Dyslipidemic Normoglycemic; DPD: Dyslipidemic Prediabetic; DD: 
Dyslipidemic Diabetic. 
3
Defining criteria: Dyslipidemia = ↓HDL and ↑TG; 
Prediabetic = IFG (fasting glucose >100-126 mg/dL) and/or IGT (2-hr 
glucose >140-<200 mg/dL, after 75g oral glucose tolerance test); Diabetes 
= 2-hr glucose >200 mg/dL, after 75g oral glucose tolerance test.
4
Not 
normally distributed after log, square root and inverse transformations; 
analyzed using Kruskal-Wallis test with Mann-Whitney post-hoc test for 
pair-wise comparisons.
5
Analyzed using one-way ANOVA with Dunette 
T3’s post-hoc test for pair-wise comparisons.6Inverse transformed to 
achieve normality;
7
Analyzed using one-way ANOVA with Tukey’s post-
hoc test for pair-wise comparisons; 
8
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0.683 
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Table 3: Pairwise Correlations among CVD Risk Factors  
 
+Correlation coefficient by Spearman’s correlation analysis 







Note: HOMA-IR was calculated according to the following   
formula: 
                 HOMA = glucose (mM) x insulin (μU/mL)/22.5 
Relationship between r P-Value 
Fasting glucose and HDL cholesterol -0.38
+
 0.001 
2-hr glucose and HDL cholesterol -0.29
*
 0.013 
Fasting glucose and LDL cholesterol 0.26 
+
 0.02 
2-hr glucose and LDL cholesterol 0.37
*
 0.001 
% 10-yr CVD risk and triglyceride  0.38
+
 <0.0001 
% 10-yr CVD risk and total cholesterol 0.34
+
 0.002 
% 10-year CVD risk and hsCRP  0.08
+
 0.478 
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Table 4: Pairwise Correlations among CVD Risk Factors and Distribution of 
TC and HDL-C in LDL and HDL Subfractions, Respectively. 
 
Figure 4: Percent 10-Yr CVD Risk among Participants with Increasing 
Degree of Hyperglycemia 
 
 
Note: Percent 10-yr CVD risk was calculated using gender specific 
algorithm that uses age, LDL-C, HDL-C, blood pressure, diabetes 
and smoking for the prediction of coronary heart disease event) 
Relationship between             r  P-Value 
% 10-yr CVD risk and distribution of the 




  0.039 
% 10-yr CVD risk and distribution of total 




% 10-yr CVD risk and distribution of total 




TC/HDL and distribution of the total 
cholesterol in the small, dense LDL 
particles. 
0.67* <0.0001 
TC/HDL and distribution of the total 
cholesterol in the smaller HDL particles. 
-0.35* 0.002 
TC/HDL and distribution of the total 





TC/HDL and distribution of the total 
cholesterol in the larger HDL particles. 
-0.84* <0.0001 
TC/HDL and distribution of the HDL 
cholesterol in the smaller HDL particles. 
0.60* <0.0001 
TC/HDL and distribution of the HDL 
cholesterol in the larger HDL particles. 
-0.56* <0.0001 
*Correlation coefficient by Pearson’s correlation analysis 
+
Correlation coefficient by Spearman’s correlation analysis 
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Data shown as mean ± SD; values with different superscripts are 
significantly different.  
2
NC: Normoglycemic normolipidemic Controls; DN: 
Dyslipidemic Normoglycemic; DPD: Dyslipidemic Prediabetic; 
DD: Dyslipidemic Diabetic 
3
Defining criteria: Dyslipidemia = ↓ HDL and ↑ TG; Prediabetic = 
IFG (fasting glucose >100-126 mg/dL) and/or IGT (2-hr glucose 
level >140-<200 mg/dL, after 75g oral glucose tolerance test); 
Diabetes = 2-hr glucose level >200 mg/dL, after 75g oral glucose 
tolerance test 
4
Not normally distributed after log, square root and inverse 
transformations; analyzed using Kruskal-Wallis test with Mann-
Whitney post-hoc test for pair-wise comparisons 
5
Sum of (%LDL-1, %LDL-2) 
6
Sum of (%LDL-3, %LDL-4) 
7
Log transformed to achieve normality 
8
One-way ANOVA was used to test the differences, and Tukey’s 
post-hoc was used to find differences between means in pair-wise 
comparisons 
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Data shown as mean ± SD; values with different superscripts 
are significantly different.  
2
NC: Normoglycemic normolipidemic Controls; DN: 
Dyslipidemic Normoglycemic; DPD: Dyslipidemic Prediabetic; 
DD: Dyslipidemic Diabetic 
3Defining criteria: Dyslipidemia = ↓ HDL and ↑ TG; Prediabetic 
= IFG (fasting glucose >100-126 mg/dL) and/or IGT (2-hr 
glucose level >140-<200 mg/dL, after 75g oral glucose 
tolerance test); Diabeties = 2-hr glucose level >200 mg/dL, after 
75g oral glucose tolerance test 
4
One-way ANOVA was used to test the differences, and 
Tukey’s post-hoc was used to find differences between means in 
pair-wise comparisons 
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Figure 6: Total Cholesterol Distribution in HDL Subfractions  
 
 
Note: TC in Larger HDL particles P<0.0001 
          TC in Intermediate HDL particles P<0.0001 
          TC in Smaller HDL particles P=0.023 
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CHAPTER 5 
DISCUSSION 
The importance of achieving and maintaining healthy, normal serum 
lipoprotein and inflammatory biomarker profiles to reduce the risk of developing 
CVD in healthy and at risk populations cannot be overstated. Some racial/ethnic 
groups, such as Mexican Americans, suffer from higher rates of CVD (24). 
Moreover, important disparities exist in CVD risk among this minority group 
compared to Whites including higher rates of overweight/obesity, insulin 
resistance and diabetes, physical inactivity, and higher prevalence of abnormal 
lipid concentrations (24). Furthermore, genetics in combination with these 
lifestyle related/environmental factors may also explain the higher prevalence of 
CVD in this population (147). In order to minimize the risk and prevent CVD 
among Mexican Americans, it is important to assess the factors that contribute to 
CVD development, and design and implement interdisciplinary interventions to 
lower risk before or as soon as the abnormal risk factors are observed.  This study 
was conducted to evaluate CVD risk among Mexican Americans by measuring 
concentrations of TC, LDL-C, HDL-C, TG and hsCRP, as well as cholesterol 
distribution in LDL and HDL subfractions. Furthermore, because of the higher 
risk to develop diabetes in this population, associations between glucose 
concentrations and the prevalence of a pattern B LDL phenotype, characterized by 
a greater proportion of LDL-C in sdLDL particles, were also evaluated.  
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Insulin Resistance and CVD Risk 
The prevalence of diabetes among Mexican Americans is of special 
concern because diabetes has been identified as a major cause of CVD related 
mortality and morbidity among Mexican Americans (118, 119). Flegal et al. (33) 
found that the prevalence of diabetes among Mexican Americans (13.9%) was 
significantly higher than among Whites (6.8%). They postulated that the 
difference could be due to socioeconomic, behavioral/environmental, or genetic 
factors. Mexican Americans were more likely to be less educated, have a larger 
family size, lower income to poverty threshold, and have higher leisure-time 
physical inactivity than Whites (33).  
In our study individuals in the DPD group had 107% higher CVD risk and 
those in the DD group had 270% higher CVD risk than the NC group, as assessed 
by the Framingham risk score algorithm. Moreover, among the participants in the 
DPD group, 15% had IFG, 10% had IGT and 75% were found to have both IFG 
and IGT. Therefore, the individuals with prediabetes who also exhibit 
dyslipidemia (low HDL-C and high TG) are more likely to have IFG and IGT, 
rather than one or the other. Among the participants in DD group, along with 2-hr 
hyperglycemia, 20% of participants had fasting normoglycemia, 35% had IFG, 
and 45% had fasting hyperglycemia.  The increased CVD risk among individuals 
with diabetes has already been established (152).  For example, the investigators 
from the Diabetes Epidemiology Collaborative analysis Of Diagnostic criteria in 
Europe (DECODE) study (153) observed that diabetic individuals had 50% higher 
risk for CVD mortality compared to the healthy controls.  In the DECODE study 
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(153) the addition of 2-hr glucose to fasting glucose significantly improved the 
prediction of CVD death among their diabetic population compared to fasting 
glucose or 2-hr glucose alone (p<0.005). Therefore 2-hr post prandial glucose 
may be a better indicator of assessing risk for developing CVD than just fasting 
glucose among diabetic individuals who also exhibit diabetic dyslipidemia. 
Much less is known about potential genetic factors that affect CVD risk 
among Mexican Americans. To elucidate more about the genetic factors, 
Voruganti et al. (144) in their Mexican-American population residing in San 
Antonio found that a specific region in the 12q gene was associated with HOMA 
values. In addition Voruganti et al. (144) also observed that this common set of 
genes regulated the variation in insulin resistance, BMI, waist circumference, 
HDL-C, and blood pressure, all of which are important components of CVD.  
In our study, individuals with the highest HOMA-IR had the worst CVD 
risk profile compared to the participants with the lowest HOMA-IR values. For 
example: the DD group had 31% more cholesterol, 29% more LDL-C, 33% less 
HDL-C, 209% more TG, 716% more cholesterol in sdLDL particles and 69% 
more HDL-C in sHDL particles compared to the group with the lowest HOMA-IR 
value (NC). We also found a positive correlation between LDL-C and fasting and 
2-hr glucose, as well as a negative correlation between HDL-C and fasting and 2-
hr glucose. These findings are comparable to those reported in studies with non-
Hispanic White participants. Bonora et al. (154) found HOMA-IR to be 
significantly correlated with most of the CVD risk factors such as BMI, HbA1c, 
HDL-C, TG, blood pressure, hsCRP, fibrinogen, sdLDL, vascular cell adhesion 
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molecule-1 (VCAM-1) and adiponectin. Bonora et al. (154) also observed that the 
individuals with insulin resistance had an increased cardiovascular events 
compared to those without insulin-resistance. Although in our study we did not 
look at the actual cardiovascular events, we found that the estimated 10-year CVD 
risk was 1.8 times more among individuals with insulin resistance (DPD) and 3.2 
times more among individuals with diabetes (DD) compared to those without-
insulin resistance (DN). Jointly, results from both studies suggest that insulin 
resistance or prediabetes not only results in alterations in glucose metabolism, but 
also an increased risk of CVD. 
Dyslipidemia  
Although per study design our participants in the three dyslipidemic 
groups (i.e. DN, DPD and DD) had low HDL-C and high TG, participants with 
insulin resistance and diabetes (i.e. DPD and DD groups) also had significantly 
higher concentrations of TC and LDL-C than participants in the NC group 
(p<0.0001; p=0.013, respectively). Among the three dyslipidemic groups, TC and 
LDL-C were significantly greater among individuals with insulin 
resistance/prediabetes (DPD) and diabetes (DD) than with just dyslipidemia (DN). 
Similarly, using the baseline data from the San Antonio Heart study, Mitchell et 
al. (152) observed that diabetic Mexican Americans had greater concentration of 
TC and LDL-C than their non-diabetic counterparts.  
We observed that participants with diabetes (DD) had 223% increased 
CVD risk as compared to non-diabetic individuals (DN) with similar lipid profiles 
(i.e. low HDL-C and high TG). In a prospective study with a large sample size 
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(n=x), Liu et al. (155) observed that diabetic participants had >200% higher 
predicted CVD risk than individuals without diabetes but similar lipid profiles. In 
contrast to our study, Liu et al. (155) selected their dyslipidemic participants 
based on high concentrations of non-HDL-C (LDL-C, TC, and TG), whereas in 
our study design we selected our dyslipidemic participants based on diabetic 
dyslipidemia i.e. low HDL and high TG. Furthermore they had individuals from 
diverse race/ethnic groups in their study, whereas our study was limited to 
Mexican-American adults.  
In our study, TC and TG were positively correlated with 10-year CVD 
risk. Because LDL-C and HDL-C are components of the algorithm used to 
estimate 10-year CVD risk, we did not calculate those associations. Laakso et al. 
(156) also reported that high LDL-C, low HDL-C and high TG were associated 
with a three-fold increase risk of cardiovascular events among diabetic 
participants. However, the participants in this study were identified during the 
hospital stay and likely represent more severe cases of diabetes than the free 
living, previously undiagnosed individuals who took part in our study.  
In a longitudinal study of dyslipidemic British men (45-69 years), Yarnell 
et al. (157) found that serum TG, TC and HDL-C were predictive of CVD risk. 
After a 10-year follow-up, the incidence of CVD was 22.6% higher in the group 
that had the highest concentrations of TC and TG and the lowest concentrations of 
HDL-C, than the group that had the most desirable concentrations of these three 
major lipids (p<0.01) (157). However, although TC, HDL-C and TG were 
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independently associated with CVD risk, no evidence of interaction was found 
between the three lipids (TC, HDL-C and TG) and 10-year CVD risk (157).  
Estimated results obtained from our study may add-on to the results from 
other studies that the combination of low HDL with raised TG concentrations 
along with other risk factors substantially increases CVD risk. Further, studies 
have shown that among Mexican Americans the lipid profile is altered in a similar 
fashion to the diabetic dyslipidemia, even when insulin resistance is present in the 
absence of diabetes (pre-diabetes) (152, 158). Therefore, more evidence is needed 
to better understand whether modifying these risk factors will reduce CVD in 
Mexican Americans with diabetes/insulin resistance. 
LDL Subfractions 
In our study, the cholesterol distribution in sdLDL particles, LDL mean 
particle size, and peak particle size were significantly different in healthy controls 
(NC) than the individuals with dyslipidemia (DN, DPD, DD) irrespective of their 
degree of hyperglycemia. Moreover, we found that participants with diabetes (DD 
group) had 4.3% more cholesterol in sdLDL and 9 Å 3% larger LDL particles size 
than healthy control individuals (NC group). In a biethnic population (Mexican 
Americans and non-Hispanic Whites), Haffner et al. (159) also observed that 
Mexican Americans had significantly smaller LDL size compared to non-
Hispanic Whites (p=0.04) (159). Moreover, they observed that higher TG, 
insulin, and glucose concentrations; lower HDL-C concentrations, and male 
gender were independent correlates of sdLDL. Similarly, Lee et al. (151) reported 
that individuals with type 2 diabetes had 11.6% greater cholesterol in sdLDL 
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(p<0.05) compared to the healthy controls. In contrast to our study, the diabetic 
participants in the study conducted by Lee et al. (151) did not have significantly 
different LDL-C concentrations compared to the healthy controls. Although Lee 
et al. (151) did not mention whether or not the diabetic participants were 
controlled for lipid lowering drug therapy, it is possible that hypolipidemic drug 
use could have influenced their results and could explain the lack of difference in 
LDL-C between the two groups. Koba et al. (160) found that individuals with 
CVD had a significantly higher amount of cholesterol in sdLDL and a lower 
amount of cholesterol in large LDL compared to the healthy middle-age controls 
regardless of having normal LDL-C concentrations achieved by lipid lowering 
drug therapy. Moreover participants with CVD had significantly smaller LDL size 
than controls regardless of the lipid lowering drug therapy (160). This suggests 
that sdLDL is a more important risk factor for CVD among dyslipidemic 
individuals with and without diabetes regardless of low LDL-C concentration. 
In our study, the distribution of cholesterol among LDL subfractions was 
analyzed by gel electrophoresis. The number of LDL particles cannot be assessed 
using this method.  Using NMR, Kathiresan et al. (91), found a relationship 
between the increase in number of sdLDL particles and cardiovascular events in 
individuals with metabolic syndrome. Kathiresan et al. (91) further observed that 
the total number of sdLDL was elevated even with the normal concentrations of 
LDL-C among these individuals. However, Kathiresan et al. (91) evaluated the 
assessment of number of sdLDL particles only in a subset of high-risk individuals 
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with metabolic syndrome. It is possible that the number of sdLDL particles will 
better predict CVD risk across a broader spectrum of participants. 
Several investigators have found a direct association between insulin 
resistance and an increased number of sdLDL particles, LDL particle size and 
concentrations of cholesterol within sdLDL.  Goff et al. (161) reported that 
insulin resistance was positively correlated with the number of sdLDL particles as 
determined by Nuclear Magnetic Resonance (NMR) analysis. Very similar results 
were observed by Garvey et al. (162), who found that when compared with 
insulin-sensitive subjects, those with insulin resistance and diabetes had more 
particles of both, LDL and sdLDL particles. In addition, they observed that 
among both groups (insulin resistance and diabetic), the concentration of 
cholesterol in sdLDL particles was increased whereas concentration of cholesterol 
in larger LDL particles was decreased (162). This indicates that having more 
cholesterol within sdLDL, decreased LDL size and increase in the number of 
LDL particles could hold importance in predicting CVD risk and/or metabolic 
syndrome even in the absence of traditional CVD risk factors such as increased 
LDL-C. 
Because of the atherogenic potential of sdLDL (96, 114, 114, 161, 162), 
having a greater proportion of cholesterol in this LDL subfraction has been 
associated with increased CVD risk. In our study, the concentration of cholesterol 
in sdLDL particles was positively correlated with 10-year CVD risk and 
TC/HDL-C.  Similarly, results from prospective studies have indicated that 
individuals with more cholesterol in sdLDL are more likely to develop CVD.  In a 
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seven-year follow-up study that included 1035 cases (who developed CVD) and 
1920 controls (who did not develop CVD) between the age of 45-79 years old, 
Arsenault et al. (96) observed that cases had significantly greater amount of 
cholesterol in sdLDL particles and significantly lower cholesterol in large LDL 
particles than controls. In our study we did not find any significant difference in 
the distribution of cholesterol in larger LDL among participants in all four groups 
(i.e. NC, DN, DPD and DD). Unlike the study by Arsennault et al. (96), our study 
was not designed to look at actual CVD events; therefore, we were only able to 
estimate the risk of having CVD in next 10-year period.  
Results from ours and other studies indicate that LDL phenotype may be 
an important risk factor for CVD, especially in minorities like Mexican 
Americans. Further, Mexican Americans are at greater risk of having insulin 
resistance/diabetes which increases the likelihood of having a pattern B LDL 
phenotype and therefore exacerbate CVD risk. 
HDL Subfractions 
The dyslipidemic individuals in our study (participants in DN, DPD and 
DD groups), irrespective of their prediabetes or diabetes status, had a lower 
proportion of HDL-C in the larger HDL particles than the healthy controls (NC 
group). The healthy controls (NC) had significantly more HDL-C in the larger 
HDL particles than the other groups, whereas those with prediabetes (DPD) had 
significantly more HDL-C in the sHDL particles. In a study that compared 
participants with insulin resistance and diabetes with individuals free of these 
conditions (controls), Garvey et al. (162) found that participants in both insulin 
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resistance and diabetes groups had sHDL particles than controls. In addition, they 
observed that among both groups (insulin resistance and diabetic), the 
concentration of cholesterol in sHDL particles increased whereas the 
concentration of cholesterol in larger HDL-C decreased such that there was no net 
significant difference in HDL-C. Further, Asztalos et al. (163) used data from 169 
men with CHD (cases), 1277 without CHD (controls) and 358 HDL cholesterol-
matched men without CHD (HDL-C matched controls). In this study, they (163) 
found that the cases had significantly lower concentrations of cholesterol in larger 
HDL subfractions compared to HDL-C matched controls; the amount of 
cholesterol in sHDL subfractions was significantly higher among cases compared 
to the controls and HDL-C matched controls. Moreover, with each 1 mg/dL 
increase in HDL-C the amount of cholesterol in larger HDL particles increased by 
a mean 0.31 mg/dL among CVD participants and by a mean 0.55 mg/dL increase 
in both controls. Moreover, results from the Framingham Offspring study (163, 
164) further indicate that the presence of insulin resistance/prediabetes decrease 
the size of cardioprotective large HDL particles, and increase the sHDL 
subfractions such that there is no significant difference in total HDL-C. This 
shows that CVD participants have a significantly different HDL subpopulation 
profile than those without CVD, and that specific HDL subfraction, particularly 
having the larger subfractions decrease the risk whereas having smaller increase 
the risk.  
 Our study found a positive association between the distribution of HDL-C 
in HDL subfractions and 10-year CVD risk, and a negative association between 
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the distributions of HDL-C in HDL subfractions. In a genetic research study, 
Watanabe et al. (164) observed that HDL particles were significantly smaller in 
individuals with low HDL-C concentrations that had a family history of low 
HDL-C (affected group) as compared to either individuals with low HDL-C but 
without family history of low HDL-C (unaffected group) or healthy individuals 
without any CVD risk factors (control group). Furthermore, among individuals in 
the affected group, the amount of cholesterol was significantly higher in sHDL 
subfractions and significantly lower in larger HDL particles than in the other two 
groups. Watanabe et al. (164) also found that the concentration of cholesterol in 
larger HDL subfractions was lower in hypertriglyceridemic participants. 
However, the affected participants had only moderately elevated concentrations of 
TG predicting that HDL subfractions may not be explained by elevation of TG. 
This was further supported when the researchers found that the unaffected group 
also had lesser concentration of cholesterol in larger HDL subfrations despite a 
comparable TG concentration to controls. This evidence suggests that observed 
changes of concentration of cholesterol in HDL subfractions may be due to an 
exposure to genetic components, which may regulate cholesterol in different HDL 
subfractions. Therefore, HDL subfractions may provide better phenotypes than 
HDL-C alone for estimating CVD risk. 
In a study with 486 Chinese individuals categorized by TC concentrations 
into those with desirable, borderline high, and high concentrations, Tian et al. 
(165) observed that as TC concentrations increased, individuals had sHDL 
particles. In addition, for each 19 mg/dL increase in TC there was 1.7mg/dL 
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decrease in the amount of cholesterol in large HDL subfractions. These findings 
suggested that elevated TC concentration impairs the maturation of the HDL 
subclasses metabolism and potentially the efficiency of reverse cholesterol 
transport (RCT).  Furthermore, Tian et al. (165) found that even with desirable 
TC concentrations, participants with elevated TG had a reduced amount of 
cholesterol in larger HDL subfractions and increased content of sHDL particles, 
which in turn puts them at greater CVD risk.  
Grandjean et al. (166) studied HDL metabolism in hypercholesterolemic 
individuals and reported low LCAT activity and high CETP activity associated 
with the increased plasma TC concentration among hypercholesterolemic 
individuals. The activity of LCAT is required for normal plasma lipoprotein 
structure and is important in HDL remodeling. LCAT may catalyze unesterified 
cholesterol to cholesterol esters (CE) and promote the conversion of sHDL 
particles to larger ones. CETP is a hydrophobic glycoprotein made by the liver 
and adipose that circulates in the plasma bound to lipoproteins. It mediates 
exchange of core lipids between VLDL-TG, LDL-TG and HDL- cholesteryl 
esters. The net effect of CETP action on HDL is depletion of CE and enrichment 
with TG, with an overall net reduction in the size of HDL particles. Therefore, if 
LCAT activity being low in hypercholesterolemic individuals then the sHDL 
particles cannot be converted into large HDL particles that possess more anti-
atherogenic properties; moreover, the increased action of CETP during 
hypercholesterolemia decreases the size of HDL particles which possess less anti-
atherogenic properties. 
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As discussed before TC, VLDL, LDL and TG are important components 
of RCT that forms HDL subfractions whereas insulin and glucose are mediators 
that shift cholesterol distribution from larger to smaller. It is important to look at 
these lipids as well as glucose parameters when assessing CVD risk by HDL 
subfractions analysis. And the measurement of HDL subfractions may provide 
useful information about CVD risk beyond that obtained from traditional CVD 
risk factors, especially in individuals with normal LDL-C. 
High-sensitivity C-reactive Protein 
A concentration of hsCRP, a marker of systemic inflammation, less than 1 
mg/L is considered to be low risk for CVD, 1-2.9 mg/L is considered to be 
moderate risk for CVD and greater than 3 mg/L is considered to be at high risk for 
CVD (21).  In our study, hsCRP concentration was elevated in all groups of 
overweight/obese Mexican Americans regardless of the presence of other 
traditional CVD risk factors. The mean value of hsCRP concentration was 
4.3+4.5 mg/L (ranging from 0.16 to 23 mg/L), which is 330% higher than the 
upper limit of normal concentration and 43% higher than the upper limit for CVD 
risk.  Using NHANES data (1999-2000; n= 2205 women and 1940 men), Ford et 
al. (167) reported a mean hsCRP concentration of 2.4+0.1 mg/L among US 
adults, ranging from 0.1 to 296 mg/L. Mexican Americans had significantly 
greater hsCRP concentrations (3.5 mg/L) followed by Blacks (3.1 mg/L) and 
Whites (2.3 mg/L) (167).  
Using the Multi-Ethnic Study of Atherosclerosis (MESA) data set, Miller 
et al. (137) found that among adults who are free from CVD risk factors, the 
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hsCRP concentration varies by gender i.e. women had 2.5 times higher 
concentration of hsCRP (10.3%) than men (4.4%). Further, in a study that 
included Mexican-American and non-Hispanic White men and women, Wee et al. 
(168) found that mean hsCRP concentrations were significantly different by race 
and ethnicity in women but not in men. Among women, hsCRP concentrations 
were the lowest in Whites (2.77 mg/L) and the highest in Mexican Americans 
(3.09 mg/L). After adjustment for age, race/ethnicity and education, body mass 
index (BMI) and waist circumference (WC) were associated with higher hsCRP 
concentrations (p < 0.001). Similarly, in a cross-sectional study that included 
3,154 women, Kelley-Hedgepeth et al. (136) found that hsCRP concentration was 
53% higher in Mexican Americans than in Whites. In Kelly-Hedgepeth’s study, a 
strong joint positive association was observed between BMI and Waist to hip ratio 
(WHR) with CRP concentrations independent of age, SES, and ethnicity. 
Therefore, from the results assessed in this study other studies, high CRP 
concentrations may be prevalent among Mexican-American women who are 
overweight/obese.  
In our study, hsCRP was not correlated with the estimated 10-year CVD 
risk or with traditional (serum lipids, serum glucose) and non-traditional risk 
factors (cholesterol distribution in LDL and HDL subfractions) for CVD. Similar 
to our study, Bowden et al. (169) found no evidence of an incremental association 
of hsCRP concentrations with CVD in diabetics as well as non-diabetics, despite 
participants being at risk for subclinical CVD (assessed measuring intima media 
thickness [IMT] and coronary artery calcification [CAC]).  However, this study 
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was limited to participants from White and African American ethnic backgrounds.  
Results as such observed in our study have not been previously reported in 
Mexican Americans/Hispanics. But as supported by NHANES data (167) and the 
studies by Miller et al.(137) and Wee et al. (168) this population 
(overweight/obese Mexican Americans, especially females), in general, have 
elevated CRP, which could contribute to not being able to find a relationship 
between CRP and CVD risk. 
 In contrast Mandell et al. (170) and Ridker et al. (171) and found that CRP 
predicts development of incident of CVD events including myocardial infarction, 
stroke, peripheral arterial disease, and sudden cardiac death. Madell et al. (170) 
found that among men CRP concentrations were raised in association with a 
variety of established cardiovascular risk factors such as high BMI (p<0.0001), 
smoking (p<0.0001), low socioeconomic status (p=0.014) and age (p=0.036). 
However after adjustment for these traditional CVD risk factors, the association 
between CRP and CVD risk became non-significant; predicting that neither CRP 
nor the systemic inflammation it represents appears to play a direct role in the 
development of CVD.  Ridker et al. (171) also found that the addition of CRP 
measurement to screening based on lipid concentrations may provide an improved 
method of identifying women at risk for cardiovascular events.  Ridker et al. 
(171) observed that CRP was the strongest predictor of the cardiovascular events 
compared to other inflammatory markers such as amyloid A, interleukin-6, and 
soluble intercellular adhesion molecule type 1 (slCAM-1), with the relative risk of 
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the events for women in the highest quartile as compared to lowest for hsCRP 
being 4.4.  
There is scant information available regarding concentration of hsCRP in 
Mexican Americans. Its applicability to screen Mexican Americans who are at 
risk for CVD is currently debated because few studies have been published 
regarding hsCRP concentrations as a predictor for CVD in this population. 
Therefore, more research regarding hsCRP as a screening tool for CVD risk 
among this population is needed.   
Using The Framingham Risk Algorithm to Predict 10-Year CVD Risk 
We used the Framingham Risk Score algorithm (148) to estimate risk of 
developing CVD in next 10-year period in our study participants. The mean 
estimated 10-year risk for developing CVD for all participants was 5.3+6.2%, 
which was derived after using the total points obtained from LDL-C based 
algorithm. Participants in the DD group had highest CVD risk compared to the 
other three groups i.e. NC, DN and DPD (p<0.0001). As expected, we found a 
significant positive correlation between 10-year CVD risk measured by using 
Framingham risk score and TC, TG, TC/ HDL-C, cholesterol distribution in 
sdLDL particles.  Furthermore, 10-year CVD risk was negatively correlated with 
the distribution of cholesterol in intermediate and large HDL particles. However, 
a significant correlation between 10-year CVD risk and hsCRP could not be 
established in this study. The Framingham risk score algorithm was derived from 
a predominantly White population from Framingham, Massachusetts (171). 
Likewise, most studies looking at the association between independent CVD risk 
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factors and 10-year CVD risk derived from the Framingham risk algorithm have 
been assessed in cohorts of White individuals (148, 172). There is limited 
research using this algorithm in other ethnic and racial cohorts, including Mexican 
Americans (172). D’Agnostino et al. (172) tested the validity of the Framingham 
risk score algorithm to accurately predict the CHD risk in six different ethnically 
diverse cohorts (n=23,424) including Whites, Blacks, Native Americans, Japanese 
American men, and Hispanic men: the Atherosclerosis Risk in Communities 
Study (1987-1988), Physicians’ Health Study (1982), Honolulu Heart Program 
(1980-1982), Puerto Rico Heart Health Program (1965- 1968), Strong Heart 
Study (1989-1991), and Cardiovascular Health Study (1989-1990). They found 
that among White and Black men and women the Framingham algorithm 
performed reasonably well for prediction of CHD events within 5-year follow-up 
period. However, among Japanese American and Hispanic men and Native 
American women, the Framingham algorithm overestimated the risk of 5-year 
CHD events. After recalibration (i.e. taking into account the prevalence of risk 
factors and underlying rates of developing CHD), the Framingham functions 
worked well in these populations. To our knowledge, there are only two studies 
published to date (170, 173) that have used the Framingham Risk Score among 
Mexican Americans. One to report CVD related deaths (173), and another that 
assessed CVD risk (167). 
Hurley et al. (173) used the Framingham risk algorithm to report CVD 
related deaths (but not to estimate the CVD risk) among individuals from several 
race/ethnic groups who died from cardiovascular events. They found that older 
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age was more strongly associated with CVD mortality in Whites (Hazard 
ratio=3.37) than Blacks (Hazard ratio=2.29) and Mexican Americans (Hazard 
ratio=2.46); when all other risk factors (sex, smoking, diabetes, elevated total 
cholesterol, low concentrations of HDL-C, and systolic blood pressure) were held 
constant, Blacks (9%) and Mexican Americans (7%) were at a higher risk for 
cardiovascular death at younger ages compared to White participants (5%). 
However, their definition of cardiovascular mortality relies on death certificate 
diagnoses, which are subject to error in the certification of the underlying causes 
of death. Also, Hurley et al. (173) were not able to measure nonfatal events, and 
by excluding these events, they may have underestimated associations between 
other risk factors and CVD among different ethnic groups. 
Aside from the Framingham Risk Score (148), there are other proposed 
algorithms (such as the UK prospective diabetes study [UKPDS] risk engine, and 
the Atherosclerosis Risk in Communities [ARIC] study risk equation) to estimate 
CVD risk (174, 175). The UKPDS Risk Engine incorporates the following 
variables: age at diagnosis of diabetes, gender, race/ethnicity, smoking status, 
concentration of HbA1c, systolic blood pressure, and TC/HDL-C (174). The 
ARIC study risk equations incorporate age, race, categories of concentrations of 
TC, categories of concentrations of HDL-C, systolic blood pressure, use of 
antihypertensive medications, and current smoking status (175). Ford et al. (158) 
observed that the 10-year risk for CVD among diabetic individuals from three 
different race/ethnic groups (Whites, African Americans and Mexican Americans) 
declined significantly between 1999-2000 and 2007-2008, whether using the 
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UKPDS Risk Engine (from 21.1% to 16.4%) or risk equations from the ARIC 
study (from 18.7% to 15.9%), or the Framingham Heart Study (from 18.6% to 
14.6%). Ford et al. (158) attributed CVD risk reduction to improved treatment for 
hypercholesterolemia and hypertension; whether this improvement was due to use 
of pharmacological agents or due to lifestyle changes is unclear. In our study the 
10-yr CVD risk significantly increased two fold with the presence of prediabetes 
along with dyslipidemia, and three fold with the presence of diabetes along with 
dyslipidemia, as compared to the healthy controls. However, the comparison of 
our study with that of Ford et al. (158) is limited because the latter study had a 10-
years prospective follow-up study design, in contrast to our comparison of four 
different groups with the cross-sectional study design. Using the different 
estimates of CVD risk resulted in some discrepancies in changes observed over 
time. In addition, when stratified by race/ethnicity, the analyses failed to 
demonstrate significant reductions in several risk factors such as smoking, 
HbA1c, and blood pressure among Whites; smoking among African Americans; 
and blood pressure and TC among Mexican Americans. This indicates that 
predicting CVD risk may require different considerations among race/ethnic 
groups based on the individual risk factors critical to these groups. 
Limitations  
Several potential limitations of our analysis deserve mention. The cross-
sectional design of the study prevents us from drawing causal inferences about the 
relationship between the CVD risk factors and risk of developing CVD in a 10-
year period. In addition, the sample size is relatively small, which may limit the 
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statistical power to detect certain significant associations between variables such 
as hsCRP and 10-year CVD risk, and cholesterol distribution in larger LDL 
particles and 10-year CVD risk. All the individuals recruited in the study were  
30 years and self-identified as Mexican American. The study did not control for 
country of birth, acculturation or other non-biological factors that may affect 
CVD risk. Individuals who were previously diagnosed with diabetes and/or were 
taking diabetic medication were excluded from the study. However, we did not 
control for the presence of other chronic diseases (known or unknown) or for 
medication usage that may influence the individual results. The study did not 
control for smoking, stress level and other acute illness, which may influence 
hsCRP concentrations. Although we attempted to minimize the confounding 
effect of adiposity by excluding normal, underweight and pregnant individuals 
from our study, controlling for obesity could have decreased our power of finding 
significant correlations between hsCRP and 10-year CVD risk because 
overweight/obesity has been documented to increase inflammatory response even 
in healthy individuals without other pertinent CVD risk factors (136, 168, 171). 
Regarding the assessment of cholesterol distribution among different 
lipoprotein subfractions, instead of NMR, we used polyacrylamide gel tube 
electrophoresis because it is a method that can be used in semiautomatic mode 
and takes only three hour with high reproducibility at a relatively low cost. NMR 
is the gold standard technique with which both particle size and total number of 
heterogeneous lipoprotein particles can be calculated. However it is expensive, 
labor intensive, and requires experienced personnel to run the analyses. 
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Our study participants were predominantly adults with mean age of 
41.6+7.8 years. Therefore, the results derived may not be entirely applicable to 
other populations including younger Mexican-American adults. In addition, we 
have used the Framingham risk score to calculate CVD risk. This measure has not 
been frequently used for Mexican Americans and may affect our study results. 
 To further evaluate CVD risk among Mexican Americans, a longitudinal 
study that includes an analysis of place of origin, age, gender and other genetic as 
well as behavioral influences is needed. More research should be conducted by 
using the Framingham risk score to predict 10-year CVD risk among Mexican 
Americans in order to check the sensitivity of the risk score in this population. 
Also, adiposity may confer a more detrimental impact on inflammation in 
Mexican Americans, and therefore future research should clarify CRP’s role in 
predicting cardiovascular risk in this ethnic minority groups. 
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CHAPTER 6 
CONCLUSION 
Even though the prevalence of CVD has decreased over the time, CVD is 
still responsible for more deaths in the US than other diseases. CVD is the major 
cause of mortality among Mexican-American adults as it is for other racial/ethnic 
groups. In our study, along with the greater concentrations of traditional CVD risk 
factors (such as TC, LDL-C) among the dyslipidemic individuals with varying 
degree of hyperglycemia (DN, DPD, DD)  than in the controls (NC), %10-year 
CVD risk increased significantly with increasing degree of hyperglycemia. In 
addition, the controls had significantly less cholesterol in sdLDL than the 
dyslipidemics, regardless of their hyperglycemic status. In addition when 
hyperglycemia was a phenotype, the greater proportion of cholesterol as well as 
HDL-C in sHDL particles was observed among dyslipidemics as compared to the 
controls.  
Given that there are few studies that had looked at lipoprotein subfractions 
and the concentrations of hsCRP in Mexican Americans, our study is an important 
contribution to the literature that have looked at hsCRP and LDL and HDL 
subfractions as the risk factors for CVD in various subset samples of Mexican 
Americans. With this cross-sectional study we were able to show the positive 
associations between %10-year CVD risk and TG, TC, TC/HDL and cholesterol 
distribution in sdLDL particles. Percent 10-year CVD risk further was negatively 
correlated with cholesterol distribution in intermediate and larger HDL-C. In 
addition, we found the TC/HDL was positively correlated with cholesterol 
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distribution in sdLDL particles and HDL-C distribution in sHDL particles; 
TC/HDL was negatively correlated with the cholesterol distribution in sHDL, 
intermediate and large HDL particles, and HDL-C distribution in the larger HDL 
particles. However, no significant association was found between %10-year CVD 
risk and hsCRP, which raises the question about the importance of measuring 
hsCRP in overweight dyslipidemic Mexican Americans with varying degree of 
hyperglycemia to predict CVD risk.  
The full association between 10-year CVD risk and other novel risk 
factors, in the presence of hyperglycemia as a phenotype, are incompletely 
understood. Therefore it is important to conduct more research to find out whether 
lipoprotein subfractions, lipoprotein size and hsCRP can be used to manage CVD 
risk more effectively and prevent future cardiovascular events in Mexican 
Americans with the varying degree of hyperglycemia before the results of this 
study can be generalized to the population. 
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